# A sum of its parts: A systematic review evaluating

# **biopsychosocial and behavioral determinants of**

# **₃ perinatal depression**

- 4 Kayla D. Longoria<sup>1\*</sup>, Tien C. Nguyen<sup>2,3</sup>, Oscar Franco-Rocha<sup>1</sup>, Sarina R. Garcia<sup>2</sup>, Kimberly A. Lewis<sup>1,4</sup>,
- 5 Sreya Gandra<sup>2,5</sup>, Frances Cates<sup>5</sup>, Michelle L. Wright<sup>1,6</sup>
- 6 School of Nursing, University of Texas at Austin, Austin, Texas, USA
- 7 <sup>2</sup> College of Natural Sciences, University of Texas at Austin, Austin, Texas, USA
- 8 <sup>3</sup> University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- 9 <sup>4</sup> Department of Physiological Nursing, School of Nursing, University of California, San Francisco
- <sup>5</sup> College of Liberal Arts, University of Texas at Austin, Austin, Texas, USA
- 11 <sup>6</sup> Department of Women's Health, Dell Medical School at The University of Texas at Austin, Austin, Texas, USA
- \* Corresponding author

14

18

19

- 13 Email: kdlongoria@utexas.edu
- Author roles: **KDL**: conceptualization, project administration, methodology, data curation, formal analysis, resources,
- writing original draft preparation. TCN, OFR: data curation, visualization, writing review and editing SRG, KAL,
- 17 MLW: data curation, writing review and editing SG: writing review and editing FC: writing review and editing

### **Abstract**

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

**Introduction** Depression is one of the most common yet underdiagnosed perinatal complications and our understanding of the pathophysiology remains limited. Though perinatal depression is considered to have a multifactorial etiology, integrative approaches to investigation are minimal. This review takes an integrative approach to systematically evaluate determinants and potential interactions among determinants of perinatal depression across four domains (i.e., biological, behavioral, environmental, social) and appraise the quality of methods applied. Methods Four databases (i.e., PubMed, CINAHL, APA PsycInfo, and Web of Science) were systematically searched to identify studies examining determinants of perinatal depression in adult perinatal persons (> 18 years). Articles were excluded if the outcomes were not focused on perinatal persons and depression or depression symptoms, the evaluation of depression was specific to a discrete facet of the perinatal period with probable psychological consequences (e.g., abortion, fetal/infant loss, adoption), or was considered grey literature. The Critical Appraisal Skills Programme and AXIS tools were used to guide and standardize quality appraisal assessments and determine the level of risk of bias. Results Of the 454 articles identified, 25 articles were included for final review. A total of 14 categories of determinants were investigated: biological (5), behavioral (4), social and environmental (5). Though only 28% of studies simultaneously considered determinants under more than one domain, a pattern of interactions with the tryptophan pathway emerged when determinants across domains were aggregated. Concerns for risk of bias were noted or were unclear for three types of bias: 13 (52%) selection bias, 3 (12%) recall bias, and 24 (96%) measurement bias. Conclusions Future research is needed to explore interactions among determinants and the tryptophan pathway; to strengthen the methods applied to this area of inquiry; and to generate evidence for best practices in reporting, selecting, and applying methods for measuring determinants and perinatal depression.

# Introduction

The leading underlying cause of perinatal death is mental health conditions [1]. Depression is one of the most common conditions to occur perinatally as it impacts every one in five perinatal persons [2, 3]. Perinatal depression denotes the manifestation of affective, somatic, and/or cognitive symptoms, ranging in severity, that can occur at any time point in the perinatal period (i.e., conception-12 months postpartum) and impairs one's ability to complete daily activities [2–4]. While impairment in functioning is already of concern due to the increased physiological, psychological, and financial demands generated by this life-stage, distal outcomes (i.e., suicide, opioid use disorder) continue to contribute to the alarmingly unabated maternal mortality rates in the US where 80% of these deaths are considered preventable [1, 5, 6]. For instance, suicide, a leading cause of maternal mortality, has tripled over the last decade and accounts for ~20% of perinatal deaths [6, 7], whereas opioid use disorder accounts for one of the most frequent causes of accidental death [1, 5, 8]. Yet, depression remains the most underdiagnosed perinatal complication in the US [2] suggesting advancements in our understanding of the risk for and development of the condition requires timely attention and response.

The heterogeneous nature of depression symptoms coupled with the stark overlap of "normal" pregnancy symptoms make early detection and intervention difficult. Therefore, the prevalence of perinatal depression is likely underrepresented in part due to the lack of diagnostic expertise in the clinicians who are most likely to interact with at-risk individuals, high variability in existing screening practices, and underreporting of symptoms due to perceived stigma [9–11]. Still, 10-20% of perinatal persons are reported to experience depression [3, 12–14].

A majority of research on the etiology of perinatal depression has attempted to dissect it into two broad camps (i.e., internal factors, external factors) [13]. Investigations are further reduced and often

limited to factors respective to a single domain (e.g., biological, behavioral, social, environmental) [12, 13, 15–17]. Evidence suggests interactions among external factors and biological factors can contribute to the onset of pathology [18]. For instance, lower levels of education, income, and occupation status have been associated with elevations in inflammatory markers, chronic disease states, and metabolic dysregulation [19]. Yet, the factors most commonly explored in relation to perinatal depression are largely external (e.g., social, environmental, behavioral), such as, social determinants of health, personal or family history of a psychiatric condition, low socioeconomic status (SES), stress, poor social support, intimate partner violence (intimate partner violence), and multiparity [12, 20, 21]. Due to the limited understanding of biological factors that may contribute to depression in perinatal populations, biological theories of depression (i.e., immune response, inflammation, tryptophan metabolism) in the general population may be useful in informing initial directions for investigations including biological factors in perinatal specific depression [19, 22–25].

Since perinatal depression is considered to have a multifactorial etiology, siloed approaches to investigation may inadvertently omit significant findings related to interactions among factors from differing domains that can advance our understanding of risk and onset. In an era of team science, integrative approaches to investigation are not only feasible but desirable to address some of the world's most complex health problems, like perinatal depression. This review aggregates existing literature across various scientific domains and uncovers novel interactions that warrant further investigations into the etiology and risk for this complex condition. Advancements in knowledge of distinct determinants and interactions will not only improve our ability to detect existing symptoms but will also progress our aptitude for determining risk status and implementing risk mitigation strategies [10]. Therefore, the purpose of this review is to take an integrative approach to systematically evaluate a) what social, environmental, behavioral, and biological determinants (i.e., immune response, inflammation,

tryptophan metabolism) have demonstrated a relationship with perinatal depression b) how such determinants effect perinatal depression, and c) the quality of the methods used in the included studies.

## **Methods**

### **Search Strategy**

The literature search took place in December 2022. The following databases were searched for articles that encompassed all or some of the specified determinants: PubMed, CINAHL, APA PsycInfo, and Web of Science. The following search terms were used across all databases in the Title/Abstract field: (depression or depressive or mdd or major depressive disorder or clinical depression or unipolar depression) AND (social or environmental or behavioral) AND (determinants or characteristics or factors) AND (tryptophan or serotonin or kynurenine or immunology or immune response or immune system or inflammation or inflammatory response or cytokines) AND (metabolites or metabolomics or metabolism) AND (pregnan\* or prenatal or perinatal or antenatal or postpartum or postnatal or matern\* or peripartum or intrapartum).

The study selection process was guided by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) methodology [26]. Search results and duplicates were managed using the open-source reference management software Rayyan [27]. Microsoft Excel was used as a screening and data extraction tool to organize articles among the six authors (KDL, MLW, SG, TCN, KL, OFR), and allowed the primary author to successively cross-check articles screened to confirm eligibility decisions before proceeding to full-text review and quality appraisal.

### **Inclusion and Exclusion Criteria**

Articles from any date were included if they focused on a timeframe within the perinatal period (i.e., conception-12 months postpartum), had participants that were 18 years or older, were available in the English language, investigated factors that belonged to at least one of the four domains (i.e., biological, behavioral, environmental, social), and had an outcome of depression or depression symptoms. We define the four domains as follows: 1) biological: individual features unique to a person that have a biological basis (e.g., genetics, brain chemistry, hormone levels) 2) behavioral: either a conscious or unconscious action or inaction in response to internal or external stimuli (e.g., dietary intake, smoking, physical activity) 3) environmental: physical surroundings or conditions a person lives or functions within (e.g., access to resources, air pollution, poor water quality, crime) 4) social: one's experiences with relationships or interactions with others (e.g., racism/discrimination, intimate partner violence, social support) [28, 29]

Articles were excluded if they were non-peer-reviewed publications, review/meta-analyses, and commentaries. Further, articles were excluded if outcomes were not specific to pregnant/postpartum individuals (i.e., partner, support persons, infant), determinants investigated were not related to depression or depression symptoms (e.g., post-traumatic stress disorder), and the outcome or evaluation of depression or depression symptoms were specific to a discrete facet of the perinatal period with implied potential for psychological consequences (i.e., abortion, fetal/infant loss, surrogacy, adoption).

## Article selection and quality appraisal

After all articles were compiled and duplicates were removed, six authors (KDL, MLW, KAL, SG, TCN, OFR) independently screened the titles and abstracts to determine which articles met inclusion criteria. All articles were then subsequently cross-checked by the primary author to make a final determination on inclusion. Of the articles that remained after the title and abstract screening, five authors (KDL, MLW, SG, TCN, OFR) independently completed a full-text review. Any concerns

related to inclusion during any of the screening processes were resolved by discussion among the primary author and the respective co-author.

Quality appraisal screening was independently conducted by two authors (KDL, TCN) to ascertain any methodological or risk of bias concerns. Since quality appraisal assessments can be subjective in nature, we selected two commonly used quality appraisal tools (i.e., Critical Appraisal Skills Programme [CASP] and AXIS), respective to study design, to guide and standardize the process [30, 31]. The studies were then categorized as having a low, moderate, high, or unclear risk of bias per three types of bias (i.e., selection bias, recall bias, measurement bias). The types of bias and levels of risk are defined in **Table 1**.

### Table 1. Definitions of types of bias and level of risk

Term	Definition
Selection bias	any non-random error in methodological decisions that influence how a study sample is acquired.
Recall bias	occurs when the data collected from the participant may not be an accurate representation of the event or information being investigated given the lapse in time from when the event occurred to when the participant is being asked to recount information about the event.
Measurement bias	any non-random error in how an outcome is measured or evaluated.
Low risk of bias	sufficient information about the methods of investigation is provided, and there are minimal concerns related to risk of bias that could compromise the validity of the findings.
Moderate risk of bias	a majority of information about the methods of investigation are provided and/or a few concerns related to risk of bias were noted that could potentially influence the validity of the findings.
High risk of bias	a significant amount of essential information about the methods of investigation are not provided and/or a considerable number of concerns related to risk of bias were noted that likely compromise the validity of the findings.
Unclear risk of bias	too few methodological details were reported by the investigators to allow for a genuine determination of the level of risk of bias.

# Data extraction and synthesis

The following data were extracted from the included articles: country, purpose or aims, study design, recruitment and sampling method, perinatal period investigated, number of time points, sample description, what determinants were investigated, methods for measuring determinants and depression, method of analysis, and findings related to the relationship among determinants and depression or depression symptoms. Once data extraction was complete, the data were organized by descending date respective to the time-period investigated (i.e., pregnancy, postpartum, perinatal) and then synthesized.

## Results and discussion

The PRISMA flow diagram provides an overview of the search results **Fig 1.** Twenty-six articles remained for full-text review and quality appraisal screening. One article was excluded [32] during quality appraisal screening due to methodological concerns making the total articles included 25 [33–57]. An overview of included articles with statistical values of significant findings per perinatal period can be found in **Tables 2-4**.

Fig 1. PRISMA flow chart diagram.

#### Table 2. Summary of included articles (pregnancy).

	PREGNANCY						
First Author	Purpose/Aims	Design#	Factor Domain	Summary of significant findings (values)			
Miyake <sup>2</sup> (2022) (N = 1744) <i>Japan</i>	Examine the association between tryptophan intake and depressive symptoms during pregnancy.	Cross- sectional <sup>1</sup>	Bh	Tryptophan intake was positively associated with being unemployed $(p = 0.0001)$ , household income $(p = 0.002)$ , education $(p = 0.01)$ , and intake levels of saturated fatty acids $(p \le 0.0001)$ , eicosapentaenoic acid plus docosahexaenoic acid $(p \le 0.0001)$ , calcium $(p \le 0.0001)$ , vitamin D $(p \le 0.0001)$ , isoflavones $(p \le 0.0001)$ , fish $(p \le 0.0001)$ and negatively associated with having ever smoked $(p = 0.0006)$ and cereal intake $(p \le 0.0001)$ . Age was negatively associated to the prevalence of depressive symptoms during pregnancy in a crude analysis $(p = 0.02)$ .  Compared with tryptophan intake in the lowest quartile, tryptophan intake in the highest quartile was related to a ↓ prevalence of depressive symptoms during pregnancy. The inverse exposure − response relationship was also significant in the crude analysis.			

				↑ tryptophan intake was independently negatively associated with the prevalence of depressive symptoms during pregnancy: the adjusted PRs (95% CIs) for depressive symptoms during pregnancy in all four quartiles of tryptophan intake (Crude PR (95% CI), 1.00; 0.95 (0.74–1.22); 0.87 (0.67–1.12); 0.57 (0.42–0.76), p=0.0001)); (Adjusted PR (95% CI), 1.00; 0.99 (0.76–1.28); 0.94 (0.71–1.25); 0.64 (0.44–0.93), p=0.04)).  These results were not changed when controlling for dietary factors.
				<b>Spontaneous preterm birth (SPTB)</b> was 2 times more frequent among those with depression compared to those without (12.4 vs. 6.3%, OR: 2.1 [95% CI: 1.10-4.04], p = 0.02)
	1) Determine whether			Those with depression had $\uparrow$ levels of specific gravity corrected <b>8-isoprostane</b> compared to those without depression (geometric mean: 299.96 pg/mL vs. 237.01 pg/mL, $p = 0.001$ ).
®Venkatesh <sup>2</sup> (2019) (N = 462)	antenatal depression was associated with two biomarkers of oxidative stress, 8-OHdG and 8-Isoprostane, and five biomarkers of inflammation. 2) assess whether the association between antenatal depression and SPTB was mediated by those biomarkers found to be significant in the primary aim.	Prospective <sup>2</sup>	В	Those with depression who had <u>prenatal antidepressant</u> exposure had $\downarrow$ levels <b>of 8-isoprostane</b> compared to those who had depression <u>without antidepressant exposure</u> (geometric mean: 362.40 pg/mL, $p = 0.03$ ); however, both groups (antidepressant exposure vs. not) had $\uparrow$ 8-isoprostane levels compared to those without <u>prenatal</u> depression (237.01 pg/mL, ANOVA $p = 0.02$ ).
US				Prenatal depression was associated with SPTB (AOR: 2.09, 95% CI: 1.09-4.03, p = 0.02). The association between 8-isoprostane and prenatal depression with STPB were ↓ when analyzed in the same regression model, which is suggested by the authors to indicate partial mediation of 8-isoprostane on the relationship between prenatal depression and SPTB (AOR for 8-isoprostane: 3.72, 95% CI: 2.14-6.46, p < 0.001; AOR prenatal depression: 1.68, 95% CI: 0.85-3.34, p = 0.13). After bootstrapping over 1,000 iterations, it was found that 27% of the effect of prenatal depression on SPTB was explained by 8-isoprostane.
				No significant findings were noted for <b>8-OHdG</b> or inflammatory markers.
	Investigate if subjects			Compared to controls, those with <u>prenatal</u> depression had $\downarrow$ levels of <b>omega-3 polyunsaturated fatty acid (3-PUFAs)</b> $(p=0.026)$ , <b>EPA</b> $(p=0.019)$ , and <b>DHA</b> $(p=0.02)$ . They also had $\uparrow$ <b>n-6/n-3 ratios.</b>
Chang (2018) with depression in pregnancy had higher levels of pro – inflammatory markers and lower levels of anti-inflammatory markers.  Case control¹ anti-inflammatory markers.	pregnancy had higher levels of pro –		В	<b>TNF-</b> $\alpha$ was the only <b>inflammatory marker</b> found to be significantly $\uparrow$ for those with <u>prenatal</u> depression versus those without $(p = 0.016)$ .
	control.	ь	No correlation between depression severity <b>PUFAs</b> and <b>inflammatory markers</b> were found. Depression duration was negatively correlated with <b>total n-3 PUFAs</b> , <b>EPA</b> and <b>DHA</b> $(r = -0.415, -0.395, -0.392, p = < 0.05)$ . Current depression was positively correlated with <b>n-6/n-3</b> ratio and <b>TNF-a</b> $(r = 0.458, 0.443, p < 0.01)$ .	

®Finy <sup>2</sup> (2018) (N = 214) US	Examine the association between childhood abuse, low socioeconomic status (SES) and inflammatory markers during pregnancy	Cross- sectional <sup>1</sup>	В, S	Childhood abuse history was positively associated with CRP and IL-6. Current SES and CRP and IL-6 were negatively associated ( $p$ 's < 0.01).  Depressive symptoms were positively correlated with IL-6 ( $r = 0.23$ , $p < 0.01$ ).
®Miller <sup>2</sup> (2018) (N =170) <i>US</i>	To evaluate the association between psychotropic medication and maternal serum inflammatory biomarkers in women with antenatal depressive symptoms (ADS) in the midtrimester.	Cross- sectional <sup>1</sup>	В	Those with <u>untreated depression</u> were more likely to be from a racial/ethnic minority group, to have a $\downarrow$ household income, to be publicly insured, have a $\downarrow$ educational level, and $\downarrow$ likely to be married. Further, they were $\uparrow$ likely to be employed than those with depression <u>non-responsive to treatment</u> but were $\downarrow$ likely to be employed than those with depression <u>responsive to treatment</u> .  There were no differences noted in serum levels of IFNy, IL13, IL6, IL8, or CRP, but TNF- $\alpha$ differed across the groups. <i>Post-hoc</i> analyses indicated those <u>non-responsive to treatment</u> ( $p = 0.02$ ) and <u>untreated depression</u> ( $p = 0.01$ ) had $\downarrow$ TNF- $\alpha$ compared to those <u>responsive to treatment</u> . No differences noted between <u>untreated depression</u> and those <u>non-responsive to treatment</u> ( $p = 0.76$ ).  When controlling for <u>race/ethnicity</u> , income, and <u>marital status</u> , a <u>linear regression</u> demonstrated both those with depression who were <u>non-responsive</u> to treatment and those who had <u>untreated</u> depression had $\uparrow$ TNF- $\alpha$ compared to those <u>responsive</u> to treatment ( $\beta = 0.27, 95\%$ CI: $0.02-0.52$ and $\beta = 0.23, 95\%$ CI $0.02-0.44$ ).
®Ross (2017) (N = 90) US	Examine the association between pregnant women's close relationships and cytokine profiles in the third trimester.	Prospective <sup>2</sup>	B, S	Timester and ranged from $r = 0.660 - r = -0.469$ with a mean $r = 0.322$ indicating a good proportion of variance in each cytokine is unique.  Romantic partner (RP) relationships with positive features (i.e., support/closeness) were associated with ↓ levels of inflammatory cytokines; RP relationships low in both positive and negative features (indifferent) were associated with cytokine profiles indicating ↑ inflammation.  Positive RP relationship was negatively associated with IL6:IL10 ratio. Further, when positive RP features were ↑ and there were ↓ RP negative features, the estimated IL6:IL10 ratios were lowest indicating a potential buffering or protective effect of positive RP relationships.  Positive and negative RP relationships were associated with IL10 levels (b(SE) = 0.031 (0.009), p = 0.001; b(SE) = 0.017 (0.007), p = 0.017).  Positive and negative RP relationships were associated with IFNy levels (b(SE) = 0.131 (0.041), p = 0.002; b(SE) = 0.095 (0.032), p = 0.004)  Neither positive and negative RP relationships were associated with IL13, IL8, IL6, and TNF-α levels.

				↑ positive RP relationship was associated with ↓ depressed mood $(r = -0.35, p = 0.001)$ and perceived stress $(r = -0.41, p < 0.001)$ whereas ↑ negative RP relationship was associated with ↑ depressed mood $(r = 0.51, p < 0.001)$ , perceived stress $(r = 0.53, p < 0.001)$ , and pregnancy distress $(r = 0.29, = 0.005)$ .
				When controlling for <b>pre-pregnancy BMI</b> , $\uparrow$ depression scores were <i>associated</i> with $\uparrow$ levels of <b>IL-6</b> ( $\beta$ = .23, $t$ (2, 55) = 1.98, $p$ = 0.05).
		Cross- sectional <sup>1</sup>	B, Bh	$\uparrow$ depression scores were marginally <i>associated</i> with $\uparrow$ <b>TNF-<math>\alpha</math></b> levels ( $\beta = 0.24$ , $t(2, 58)$ , $p = 0.06$ ).
	Examine associations among perceived stress, current			Depressive symptoms were <i>positively correlated</i> with <b>perceived stress</b> $(r = 0.050, p < 0.01)$ .
®Christian (2009) (N = 60) US	depressive symptoms, and serum inflammatory markers among pregnant			Those classified as <b>unhappy about their pregnancies</b> had $\uparrow$ depressive symptoms compared to those who were happy about their pregnancy (mean CES-D = 22, SD = 10; mean CES-D = 16, SD = 10, p = 0.04).
	women from primarily lower socioeconomic backgrounds.			Those reporting $\downarrow$ social support had $\uparrow$ depressive symptoms $(p < 0.05)$ , and those with $\uparrow$ frequent hostile and insensitive social interactions also had $\uparrow$ depressive symptoms $(p < 0.01)$ .
				After <i>controlling</i> for <b>social support</b> , <b>hostile and insensitive social interactions</b> remained <i>associated</i> with depressive symptoms ( $\beta = 0.17$ , $r(1, 59) = 1.25$ , $p = 0.21$ ).

Author<sup>2</sup> = secondary analysis; Design<sup>#</sup> = Design + Number of timepoints investigated; Domain of factors investigated in relation to depression: B = Biological, Bh = Behavioral, E = Environmental, S = Social; *Values (when provided)* = statistical values respective to analysis; Factors investigated in relation to depression **bold**; Timeframe and/or groups investigated <u>underlined</u>.

®Study reported race/ethnicity

Table 3. Summary of included articles (postpartum).

	POSTPARTUM						
First Author	Purpose/Aims	Design#	Factor Domain	Summary of significant findings (values)			
Achytes (2022) (N = 130) US	Investigate whether a pro-inflammatory status in plasma, together with changes in the kynurenine pathway activity, is associated with the development of severe depression and suicidal behavior in the post-partum.	Case- control <sup>1</sup>	B, Bh	↑ IL-6, IL-8 ↑ PPD (OR IL-6 = 3.0, 95% CI = 1.37 – 6.6; OR IL-8 = 3.32, 95% CI = 1.32 – 8.34, per pg/ml increase)  ↓ IL-2 ↑ PPD (OR = 2.34, 95%CI = 1.35–4.05, p = 0.002, per pg/ml decrease)  ↓ serotonin ↑ odds of PPD (OR = 1.43 per nM decrease in serotonin, 95% CI: 1.07 – 1.92, p = 0.016)  ↑ Kynurenine/serotonin ratio ↑ PPD (OR = 1.35 per unit increase, 95% CI: 1.03 – 1.79, p = 0.038)  Sensitivity analysis using depression scores: models for IL-8, IL2, serotonin, serotonin/kynurenine, and quinolinic acid were significant; (linear regression, Beta 3.9, Standardized Beta 0.22, p = 0.006), (linear regression, Beta −2.3, Standardized Beta −0.23, p = 0.005), (linear regression, Beta −1.3, Standardized Beta −0.24, p = 0.003), linear regression, Beta −1.1, Standardized Beta 0.22, p = 0.009), linear regression, Beta −4.3, Standardized Beta −0.18, p = 0.022)			

				<b>↓ serotonin</b> was associated with <b>current</b> and <b>history</b> of <b>suicidal behavior</b> and $\uparrow$ odds of <b>completed suicide</b> attempt during <u>pregnancy</u> . (OR: 0.51[0.32, 0.8]1, $p = 0.005$ ), (OR: 0.50 [0.29, 0.87], $p = 0.013$ ), (OR: 0.51, [0.31, 0.84], $p = 0.007$ )
				Those with <u>probable depression</u> were $\uparrow$ likely to belong to the <b>middle SES group</b> $(p=0.002)$ , had more than one <b>child</b> $(p=0.002)$ , be dissatisfied with their marriage $(p<0.001)$ , be dissatisfied with the gender of their child $(p<0.001)$ , and had $\uparrow$ rates of <b>cesarean delivery</b> $(p=0.014)$ . They also reported $\downarrow$ <b>milk</b> $(p<0.001)$ , meat $(p=0.012)$ , and $egg$ $(p=0.002)$ intake.
				Median <b>total B12</b> levels and <b>cB12</b> were $\downarrow$ in <u>cases</u> compared to <u>controls</u> $(p < 0.001)$ . <b>Methyl malonic acid (MMA)</b> – marker of functional deficiency of vitamin B12 – was $\uparrow$ <u>cases</u> compared to <u>controls</u> $(p = 0.002)$ .
Dhiman <sup>2</sup> (2021) (N = 660) <i>India</i>	Explore the association between vitamin B12 and probable PPD in South Indian population.	Cross- sectional <sup>1</sup>	В	After adjusting for SES, martial dissatisfaction, unplanned pregnancy, and type of delivery, the regression model indicated the likelihood of postpartum depression to $\downarrow$ by 0.39 for ever unit $\uparrow$ in total vitamin B12 ( $OR = 0.394$ ; 95% $CI$ : 0.189-0.822, $p = 0.009$ ) and by a factor of 0.29 ( $OR = 0.293$ ; 95% $CI$ : 0.182-0.470, $p < 0.001$ ) for cB12. MMA ( $OR = 2.04$ ; 95% $CI$ : 1.53-2.11, $p < 0.001$ ) and 5-methyl tetrahydrofolate (THF) ( $OR = 3.18$ ; 95% $CI$ : 1.42-6.08, $p = 0.001$ ) were found to be predictors of PPD.
				After adjusting for SES, martial dissatisfaction, unplanned pregnancy, and type of delivery, a significant negative association among serotonin and depression remained ( $\beta = -0.16$ , $p = 0.005$ ), as did a positive association among MMA ( $\beta = 0.161$ , $p = 0.001$ ), homocysteine (hcy) ( $\beta = 0.155$ , p = 0.005), and THF ( $\beta = 0.118$ , p = 0.010) and depression.
				The <i>path analysis</i> model with total <b>vitamin B12</b> as the predictor, depression score as the outcome variable, and <b>MMA</b> as the <i>mediator</i> was significant $(p < 0.001)$ .
				There were significant differences in <b>education</b> and <b>mode of delivery</b> among those with <u>PPD</u> and those <u>without</u> .
Rihua <sup>2</sup> (2018) (N = 84) <i>China</i>	To determine associations between PPD and plasma neurotransmitters.	Case control <sup>1</sup>	В	Plasma levels of <b>serotonin</b> (5-hydroxytryptamine or 5-HT) and <b>neuropeptide Y</b> (NPY) were $\downarrow$ in those with PPD compared to <u>controls</u> $(p < 0.05 \text{ or } p < 0.01)$ whereas <b>norepinephrine</b> (NE) and <b>substance P</b> (SP) were $\uparrow$ in PPD cases versus <u>controls</u> $(p < 0.05)$ . No differences were found for <b>dopamine</b> (DA).  A <i>negative correlation</i> among depression scores and <b>serotonin</b> and NPY $(p < 0.05 \text{ or } p < 0.01)$ were present
				as well as a <i>positive correlation</i> among depression scores with <b>NE</b> and <b>SP</b> $(p < 0.01 \text{ or } p < 0.01)$ .
Veen (2016) (N = 42) Netherlands	To investigate if alterations in tryptophan degradation in the postpartum period are	Case control <sup>1</sup>	В	Those considered to be "healthy" postpartum participants were $\uparrow$ likely to be <b>breastfeeding</b> at the time of blood collection ( $p < 0.001$ ).

	associated with the occurrence of postpartum depression and postpartum psychosis.			Physiological postpartum period:  Healthy postpartum (PP) participants had ↓ serum levels of kynurenic acid (KA) compared to healthy non-PP controls (p < 0.001).  All PP participants had ↑ levels of 3-OH-kynurenine (3HK) (p = 0.011); the KA/kynurenine (KYN) ratio was ↓ in healthy PP participants (p < 0.001) suggesting a strong inhibition of the kynurenine aminotransferases (KAT) enzymes during the first 2 months PP.  The 3HK/KYN ratio was ↑ in healthy PP participants with a median time of 22 days PP (p = 0.021), but not in healthy PP participants with a median time of blood collection 40 days PP. The authors suggest this indicates ↑ activity of the kynurenine-3-monooxygenase (KMO) enzymes in the first month of the physiological PP period and then the gradual returning to "normal" levels.  The serotonergic pathway (5HIAA)/KYN ratio was ↓ in healthy PP participants suggesting that the breakdown of tryptophan (TRP) is biased towards the KYN pathway and away from the serotonergic pathway in the physiological PP period (p = 0.009).  "Healthy" PP participants had ↓ serum levels of TRP (p < 0.001), and ↑ levels of KYN (p = 0.002) compared to healthy non-PP participants, and consequently the TRP breakdown index was also ↑ (p < 0.001).  KYN was ↓ in cases compared to controls (p = 0.001), and accordingly cases had a ↓ tryptophan breakdown index compared to controls (p = 0.035).
Comasco (2011) (N = 272) Sweden	Examine whether genetic variations in the monoaminergic neurotransmitter system, together with environmental stressors, contribute to the development of PPD symptoms	Case control <sup>2</sup>	В, S	Associations between genetic polymorphisms and PPD symptoms were significant only at the 6-week time point, not at 6 months (data not shown).  COMT-Val <sup>158</sup> Met with ↑ risk for Met carriers was associated with PPD.  Previous psychiatric contact, significant life events, and maternity stressors were associated with PPD symptoms.  Gene-by-gene interactions were present for COMT-MAOA in relation to PPD symptoms. Low MAOA activity carriers with the Met variant of COMT was related to PPD symptoms; high MAOA activity variant was associated with PPD symptoms only when combined with the Met allele of COMT; short 5HTT allele was associated with PPD symptoms only when combined with the Met allele of COMT.  COMTVal <sup>158</sup> Met was associated with PPD symptoms in the presence of previous psychiatric contact and maternity stressors, while MAOA-uVNTR was associated with PPD symptoms only in the presence of maternity stressors.  The logistic regression analysis demonstrated an association among PPD symptoms and COMTVal <sup>158</sup> Met, previous psychiatric contact, and maternity stressors.  The model explained 30% variance. After stratifying for previous psychiatric contact, the gene-environment

				interaction model indicated those with <b>previous psychiatric contact</b> had a <i>main effect</i> of <b>COMT-Val</b> <sup>158</sup> <b>Met</b> and <b>5HTT-LPR</b> with an <i>explained variance of</i> 40%.
Bailara (2006) (N =50) France	Assess the correlation of intensity of baby blues, with the intensity of metabolic changes and brain tryptophan availability	Cross- sectional <sup>1</sup>	В	Total plasma <b>TRP</b> exhibited a <i>mild</i> $(+19\%)$ \hftarrow\hfrarrow
Moses- Kolko <sup>2</sup> (2008) (N =16) <i>US</i>	To measure brain serotonin-1A (5HT1A) receptor binding potential (BP) in healthy and depressed postpartum women.	Cross- sectional <sup>1</sup>	В	There was an effect of <b>breastfeeding status</b> on <b>hypothalamic-pituitary-ovarian axis</b> hormone concentrations <b>estradiol, progesterone, LH, FSH,</b> and <b>prolactin</b> [Wilks' lambda = 0.2056; $F(5, 10) = 7.73$ , $p = 0.003$ ]. A post-hoc analysis showed <b>breastfeeding</b> was associated with $\downarrow$ <b>estradiol</b> [ $F(1, 14) = 8.31$ , $p = 0.01$ ], <b>progesterone</b> [ $F(1, 14) = 4.33$ , $p = 0.06$ ], and <b>FSH concentrations</b> [ $F(1, 14) = 5.18$ , $= 0.04$ ] and $\uparrow$ <b>prolactin concentrations</b> [ $F(1, 14) = 26.25$ , $p = 0.0002$ ]. <b>Serotonin receptor (5HT1A) binding</b> in the three a prior regions of interest ( <b>mesiotemporal cortex, left lateral orbitofrontal cortex, and subgenual anterior cingulate cortex)</b> demonstrated a main effect of depression [ $F(3, 12) = 13.67$ , Wilks' lambda = 0.23, $p = 0.0004$ ].  Post hoc analysis detected significant depression effects on $\downarrow$ in the <b>mesiotemporal cortex</b> [ $21.6\%$ mean decrease; $F(1, 140 = 22.5$ , $p = 0.0003$ ], <b>subgenual cingulate cortex</b> [ $27.65$ mean decrease; $F(1, 14) = 23.4$ , $p = 0.0002$ ], and <b>left lateral orbitofrontal cortex</b> [ $17.9\%$ mean decrease; $F(1, 14) = 7.13$ , $p = 0.018$ ] regions. There were also associations with reductions in the
				secondary ROI $[F(5, 10) = 3.24, Wilks' lambda = 0.38, p = 0.054]$ , and the most significant $\downarrow$ were in the <b>right</b> lateral orbitofrontal cortex $[23.4\%$ mean decrease; $F(1, 14) = 8.72, p = 0.011]$ and pregenual anterior cingulate cortex $[23.4\%$ mean decrease; $F(1, 14) = 17.2, p = 0.001]$ .

Author<sup>2</sup> = secondary analysis; Design<sup>#</sup> = Design + Number of timepoints investigated; Domain of factors investigated in relation to depression: B = Biological, Bh = Behavioral, E = Environmental, S = Social; *Values (when provided)* = statistical values respective to analysis; Factors investigated in relation to depression **bold**; Timeframe and/or groups investigated <u>underlined</u>.

®Study reported race/ethnicity

#### Table 4. Summary of included articles (perinatal).

PERINATAL					
First Author	Purpose/Aims	Design#	Factor Domain	Summary of significant findings (values)	
®Sha (2022) (N=114) US	To determine whether cytokines and kynurenine metabolites can	Prospective <sup>4</sup>	В	↑ IL-1β, IL-6, and QUIN were associated with ↑ depression severity and/or ↑ odds of having depression (Percent change in $OR(CI)$ : 32.3% (7.0, 63.6), 58.4% (22.1, 111.7), 91.6% (15.0, 232.0)	

	predict the development of depression in pregnancy.			IL-6 performed best in <i>predicting</i> depressive symptoms; however, KYN, QUIN, KYN/TRP ratio (rKT) also produced good predictions (AUC = 0.79 and 0.8 by Bayesian ordinal and logistic regression, respectively; ROC AUC > 0.7). Precision recall analyses confirmed predictive value of model.  The leave-one-out cross validation method indicated the predictability of the model would be optimal from mid-to late pregnancy (2nd to 3rd trimester). The full model nominally outperformed individual markers for predicting risk of significant depressive symptoms.  Ordinal and logistic regression full models had ROC AUC = 0.83, PR AUC = 0.41.  Fiber consumption was slightly ↓ in cases compared to
®Kimmel (2022) (N = 30) <i>US</i>	Analyze trajectories of serotonin and tryptophan-related metabolites, bile acid metabolites, and microbial composition related to psychiatric history and current symptoms across the perinatal period.	Pilot³	В	controls (determined too small a sample to calculate p-values).  Mean serotonin level ↑ from pregnancy to postpartum (p = 0.0002 for 3rd trimester (V2) to 5-10 weeks postpartum (V3); p = 0.002 for 1st or 2nd trimester (V1) to V3). NEOP level trajectories followed a different pattern than serotonin by ↑ from V1 to V2 (p < 0.0001) and then ↓ postpartum (p = 0.005). Mean KYN ↑ from V1 to V2 (p = 0.003) and ↑ again from V2 to V3 (p = 0.004). The KYN/TRP ratio was ↑ at V2 and V3 compared to V1 (p < 0.0001; p < 0.0001). KA was ↑ at V3 compared to both √2 (p = 0.003) and √1 (p = 0.0004).  Primary bile acids:  Chenodexycholic acid (CDCA) ↑ from V2 to V3 (p < 0.0001) with an overall ↑ from earlier √1 to √3 (p = 0.0003); Glycochenodeoxycholic acid (GCDCA) ↑ from √2 to √3 (p < 0.0001); Taurochenodeoxycholiate (TCDCA) ↓ from √2 to √3 (p = 0.001); Glycocholic acid (GCA) ↑ from √1 to √2 (p = 0.003) and ↑ from √1 to √3 (p = 0.005); Taurocholic acid (TCCA) ↑ from √1 to √2 (p = 0.003) and ↑ from √1 to √3 (p < 0.0001).  Secondary bile acids:  Glycoursodeoxchoilic acid (GUDCA) ↓ from √2 to √3 (p < 0.0001).  Secondary bile acids:  Glycoursodeoxchoilic acid (GUDCA) ↓ from √2 to √3 (p < 0.0001).  Glycolithocholic acid (GLCA) ↑ from √2 to √3 (p < 0.0001); Glycolithocholic acid (GLCA) ↑ from √2 to √3 (p < 0.0001); Glycolithocholic acid (GLCA) ↑ from √2 to √3 (p < 0.0001); Glycolithocholic acid (GLCA) ↑ from √2 to √3 (p < 0.0001); Glycolithocholic acid (THCA), and tarodeoxycholate hydrate (TDCA) ↓ from √2 to √3 (p < 0.0001); p = 0.0001; p = 0.0003; p < 0.0001; p = 0.0001; p = 0.0003; p < 0.0001; p = 0.0003; p < 0.0001) and levels of Glychoyocholic acid (GHCA), Tauro alpha-murcholic acid (TAMCA), Taurohyocholic acid (THCA), and tarodeoxycholate hydrate (TDCA) ↓ from √2 to √3 (p < 0.0001); p = 0.0003; p < 0.0001); p = 0.0003; p < 0.0001) and V3 were ↓ than earlier in pregnancy (p < 0.0001) from √2 to √3 (p < 0.0001); p = 0.0003; p < 0.0001).  TUDCA, TDCA, and TCA were associated with change in NEOP from √1 to √2 (p = 0.011; q = 0.021; q

				Metabolites and microbiome:  Alpha diversity did not significantly change across the perinatal period. ↑ bile acid GUDCA and UDCA levels were associated with ↓ alpha-diversity across all 4 indices (evenness, Faith's phylogenetic diversity, count of observed OTUs, Shannon entropy).  ↑ CDCA was associated with ↓ alpha diversity for the evenness index and Shannon index only, and also only when first trimester participants were included.  Certain bacterial genera were associated with UDCA and TUDCA, primarily in the order Clostridiales and family Cachnospiraceae. THcA was also associated with Riseburia.
®Tebeka <sup>2</sup> (2021) (N = 3,252) France	Assess the relationship between childhood trauma (CT) and perinatal depression, considering types of CT	Case control <sup>3</sup>	S	psychiatric history $(q = 0.033)$ .  Those reporting <b>childhood trauma</b> (CT) were \(^1\) likely to be $< 26$ years old $(8.1\% vs. 4.5\%; OR = 1.8; 95\% CI: 1.2-2.6) > 39$ years old $(11\% vs. 7\%; OR = 1.9; 95\% CI: 1.2-2.9)$ , single $(6.7\% vs. 2.7\%; OR = 2.6; 95\% CI: 1.5-4.2)$ , have a lower level of education $(18.1\% vs. 6.8\%; OR = 3.0; 95\% CI: 1.8-3.6)$ , and \(^1\) likely to have been unemployed $(14.1\% vs. 6.1\%; OR = 2.5; 95\% CI: 1.8-3.6)$ .  Those with CT had a \(^1\) risk of either depression, anxiety, or suicide attempts compared those without $(61.6\% vs. 40.8\%; OR = 2.3; 95\% CI: 1.8-2.9)$ , and a personal history of depression, anxiety, or suicide attempts were \(^1\) frequent in those with CT (depression: $OR = 2.2; 95\% CI: 1.7-2.7$ ; anxiety: $OR = 2.3; 95\% CI: 1.7-3.0$ ; suicide attempt: $OR = 5.4; 95\% CI: 3.5-8.4$ )  Depression was \(^1\) common in those with a CT regardless of type of CT, and the difference was significant for emotional, physical, and sexual abuse as well as emotional neglect $(p < 0.05 \text{ for each})$ . The types of CT demonstrated specific associations with different timing of depression onset. Emotional neglect was associated with depression during pregnancy $(aOR = 2.1; 95\% CI: 1.2-3.8, p = 0.012)$ ; sexual abuse with both early and late onset PPD $(aOR = 2.3; 95\% CI: 1.2-4.6; aOR = 2.4; 95\% CI: 1.2-4.9$ , respectively); emotional abuse was associated only with late PPD $(aOR = 2.7; 95\% CI: 1.4-5.1)$ .  A dose effect was present between CT types and risk of depression. When 1 type of CT was present there was a \(^1\) risk of depression $(aOR = 1.6; 95\% CI: 1.1-2.3, p = 0.015)$ , whereas, when 2+ types of CT were present the risk further \(^1\) $(aOR = 2.1; 95\% CI: 1.3-3.3)$ even after adjusting for history of depression and sociodemographic covariates.
Nazzari (2020) (N = 97) <i>Italy</i>	Describe the cross- sectional and longitudinal association between	Prospective <sup>4</sup>	В	↑ <u>prenatal</u> <b>Kyn</b> levels were <i>associated</i> with $\downarrow$ depressive symptoms in <u>late pregnancy</u> ( <i>estimate</i> = -0.002, SE = 0.001, $p = 0.03$ ) after adjusting for maternal age.

	tryptophan, kynurenine, and kynurenine/tryptophan ratio and depression symptoms in late pregnancy through the first year postpartum 2) examine the role of inflammatory (IL-6) and stress (cortisol) markers in moderating any associations 3) determine if specific to depressive symptoms or can be replicated with anxiety given high concurrence of these disorders			Pre-pregnancy BMI was mildly associated with IL-6 levels $(r = 0.23, p = 0.03)$ in preliminary analysis but adjusting models for BMI did not alter the direction or significance of findings.  **Model 2:**  There was a three-way interaction among prenatal Trp levels, IL-6, and slopes of time on depression scores $(ps < 0.05)$ . \$\rightarrow\$ levels of prenatal Trp and \$\gamma\$ IL-6 were associated with \$\gamma\$ depressive symptoms in late pregnancy $(p = 0.04)$ and with the change in depressive symptoms from pregnancy to three postpartum time points $(ps = 0.04)$ .  **Model 3:**  A three-way interaction among the KYN/TRP ratio, IL-6, and the depression scores trajectory from pregnancy to 12 months postpartum. \$\rightarrow\$ levels of prenatal KYN/TRP ratio and \$\gamma\$ levels of IL-6 were associated with \$\gamma\$ depressive scores at delivery $(p = 0.05)$ and 12 months postpartum $(p = 0.004)$ and with a flatter trajectory of change in depressive symptoms from pregnancy to 12 months postpartum $(p = 0.048)$ . Conversely, at \$\gamma\$ levels of KYN/TRP ratio and \$\gamma\$ IL-6 levels were associated with a \$\psi\$ in depressive scores from pregnancy to 3 $(p = 0.03)$ and 12 months $(p = 0.014)$ postpartum.
Garman <sup>2</sup> (2019) (N = 384) South Africa	Identify trajectories of perinatal depressive symptoms and their predictors among lowincome South African women who were already at risk of depression during pregnancy.	Prospective <sup>4</sup>	Bh, S, E	Food insecurity predicted classification of either prenatal only depression or prenatal and postpartum depression. The odds of being classified in the prenatal and postpartum depression trajectory was 2.5 greater (95% CI: 1.21-5.15; p = 0.013) among participants who reported being severely food insecure.  Overall levels of social support at baseline ↓ the odds of belonging to the prenatal and postpartum depression class (OR = 0.97, 95% CI: 0.95-0.99; p = 0.011). When looking at specific types of support, only a ↑ level of family support (OR = 0.91, 95% CI: 0.86-0.96; p = 0.001) or ↑ level of support from a significant other (OR = 0.94, 95% CI: 0.88-1.00; p = 0.046) ↓ the odds of being classified into the prenatal and postpartum depression class.  Those who reported IPV at baseline were 2.8 times ↑ likely (95% CI: 1.23-6.52; p = 0.014) to belong to the prenatal and postpartum depression class were ↑ among those who reported greater functional impairment (OR = 1.03, 95% CI: 1.02-1.06; p = 0.002), heavy drinking during pregnancy (OR = 2.12, 95% CI: 0.03-4.37; p = 0.042), had current (OR = 2.77, 95% CI: 1-32-5.80; p = 0.007) or lifetime diagnosis of depression (OR = 2.85, 95% CI: 1.38-5.87; p = 0.004), and high risk of suicide (OR =
Teshigawara (2019) (N = 132) Japan	To determine whether cytokines and kynurenine metabolites can predict the development of	Prospective <sup>3</sup>	В	2.58, 95% CI: 1.19- 5.61; $p = 0.017$ ).  In the non-depressed group: <b>TRP</b> , <b>KYN</b> , <b>3HK</b> , and <b>KA</b> were $\uparrow$ postpartum compared to pregnancy (two-way repeated ANOVA, <b>Trp:</b> $F_{group}$ ( $_{3,128}$ ) = 1.44, $p = 0.234$ , $F_{period}$ ( $_{1,128}$ ) = 64.3, $p < 0.0001$ , $F_{group x period}$ ( $_{3,128}$ ) = 0.376, $p = 0.771$ ; <b>Kyn:</b> $F_{group}$ ( $_{3,128}$ ) = 0.927, $p = 0.430$ , $F_{period}$ ( $_{1,128}$ ) = 96.4, $p < 0.01$ , $F_{group x period}$ ( $_{3,128}$ ) = 6.09, $p = 0.001$

	depression in pregnancy.			< 0.01; 3HK: F <sub>group</sub> (3, 128) = 0.0662, p = 0.978, F <sub>period</sub> (1, 128) = 6.09, p < 0.05, F <sub>group x period</sub> (3, 128) = 1.98, p = 0.120; KA: F <sub>group</sub> (3, 128) = 1.52, p = 0.213, F <sub>period</sub> (1, 128) = 2.11, p = 0.149, F <sub>group x period</sub> (3, 128) = 5.32, p < 0.01). In the postpartum depressed group: KYN and KA were ↑ during pregnancy, but 3HAA during the postpartum period was ↓ than that of the non-depressed group. No differences were noted in TRP or its metabolites between the temporary gestational depressive group or the continuous depressive group and the non-depressive group. The ratio of KYN in the postpartum period compared to that during pregnancy was significantly ↓ in the postpartum depressive group compared to the non-depressive group (one-way ANOVA, F(3, 128) = 5.27, p < 0.01).
				In the <u>postpartum depressive</u> group <b>KYN/TRP</b> and <b>KA/KYN</b> ratio during <u>pregnancy</u> were ↑ than those in the <u>non-depressive</u> group. <b>KYN/TRP</b> during <u>postpartum</u> to that during <u>pregnancy</u> was significantly ↓ than the <u>non-depressive</u> group (one-way ANOVA, F <sub>(3, 128)</sub> = 4.54, p < 0.01). <b>KYN, KA,</b> and <b>KYN/TRP</b> , and <b>KA/KYN</b> ratio during pregnancy were ↑ and <b>3HAA</b> during postpartum was ↓ in
				the postpartum depressive group compared to non-depressive group. <b>KYN, KA,</b> and <b>KYN/TRP</b> during pregnancy was correlated with depression scores during the postpartum period (Pearson's correlation: <b>KYN</b> : $r(77) = 0.330$ , $p < 0.01$ , <b>KA</b> : $r(77) = 0.278$ , $p < 0.05$ , <b>KYN/TRP</b> : $r(77) = 0.229$ , $p < 0.05$ , <b>KA/KYN</b> : $r(77) = 0.221$ , $p = 0.05$ ). There was a negative relationship between <b>3HAA</b> levels during postpartum period and depression scores (Pearson's
	Analyze trajectories of			correlation: $r(77) = -0.259$ , $p < 0.05$ ).  The percentage of depressed participants was $\downarrow$ in the <b>intervention group</b> compared to the control group at week 38 (18.6% vs. 35.6%) ( $\chi^2 = 4.190$ ; $p = 0.041$ ) and at 6 weeks postpartum (14.5% vs 29.8%) ( $\chi^2 = 3.985$ ; $p = 0.046$ ).  Significant differences were noted in the <i>multiple imputation analysis</i> at 38 weeks (18.6% vs. 34.4%) ( $\chi^2 = 4.085$ ; $p = 0.049$ ).
Vargas- Terrones (2017) (N = 124) Spain	serotonin and tryptophan-related metabolites, bile acid metabolites, and microbial composition related to psychiatric history and current symptoms across the perinatal period.	Randomized control trial <sup>3</sup>	Bh	A <b>treatment effect</b> was found in the per-protocol ( $F_{2, 220} = 3.798$ ; $p = 0.024$ ) and in the <i>simple imputation</i> ( $F_{2,244} = 3.351$ ; $p = 0.037$ ) analyses. Differences were also found in the <i>group-time interaction</i> between gestational weeks 12-16 (baseline) and 6 weeks postpartum ( $p = 0.014$ ) in the per-protocol analysis.  Differences were found in the <b>group-time interaction</b> between depression scores at baseline and gestational
				week 38 ( $p = 0.046$ ), and between <u>baseline</u> and <u>6 weeks</u> postpartum ( $p = 0.025$ ), with a $\downarrow$ depression score in the intervention group than in the <u>control group</u> .  The participants considered to have <b>excessive gestational</b> weight gain, the <u>control group</u> had a $\uparrow$ percentage of depression at <u>week 38</u> ( $\chi^2 = 9.489$ ; $p = 0.002$ ) and at <u>6</u> weeks postpartum ( $\chi^2 = 5.202$ ; $p = 0.023$ ).

				The percentage of depressed women was $\downarrow$ in the intervention group compared to the control group at week 38 for those with pre-pregnancy normal-weight BMI ( $\chi^2 = 4.688$ ; $p = 0.030$ ).
®Robertson Blackmore <sup>2</sup> (2016) (N = 171) US	Blackmore <sup>2</sup> cytokine levels, a candidate mechanism (N = 171) accounting for poor	Prospective <sup>4</sup>	B, S	<b>Lifetime exposure to IPV</b> was <i>associated</i> with a range of psychiatric conditions, including generalized anxiety disorder, post-traumatic stress disorder, and depression. Further, <b>IPV</b> was <i>associated</i> with experiencing depression during both <u>pregnancy</u> and <u>postpartum</u> .
				Those with a history of <b>IPV</b> had $\uparrow$ levels of <b>TNF-</b> $\alpha$ ( $z = -2.29$ , $p < 0.05$ ) compared to those with no IPV exposure.
				After <i>controlling</i> for participants characteristics, a greater change in the levels of <b>IL-6</b> during <u>pregnancy</u> compared to the <u>postpartum period</u> remained ( $\beta = 0.21$ , $p = 0.04$ ). This trend was different according to <b>IPV status</b> . Those who <b>experienced violence</b> had smaller changes in <b>IL-6</b> across the time points compared to those <u>not exposed to violence</u> ( $\beta = -0.36$ , $p = 0.04$ ). From <u>6 weeks to 6-month PP</u> , those <b>exposed to violence</b> had a greater $\downarrow$ in <b>IL-6</b> compared to those <u>without exposure</u> ( $\beta = 0.36$ , $p = 0.04$ ).
				The change in <b>TNF-<math>\alpha</math></b> levels at <u>32 weeks' gestation to 6</u> weeks <u>PP</u> was $\uparrow$ than the change from <u>6 weeks to 6</u> months <u>PP</u> ( $\beta = 1.54$ , $p < 0.01$ ).
Fasching (2012) (N = 361) <i>Germany</i>	Identify trajectories of perinatal depressive symptoms and their predictors among lowincome South African women who were already at risk of depression during pregnancy.	Prospective <sup>3</sup>	В	Haplotype block analysis showed that 10 of the 14 haplotypes of the <i>THP2</i> gene were assembled in three haplotype blocks (B1-B3). <b>SNPs rs6582071</b> and <b>rs11178997</b> (haplotype A) were also analyzed given these SNPs are known to be of functional relevance.
				Genotype-phenotype association in haplotype Block A: The most common haplotype was GT (63.4% homozygous for this haplotype and 31.6% had one allele for GT). The extremely rare haplotype GA (only one carrier) was excluded.
				The <i>linear mixed model</i> indicated an effect for <b>time</b> $(p < 0.00001, F-test)$ as well as haplotype <b>GT</b> $(p = 0.02, F-test)$ and the <b>interaction of time and haplotype GT</b> $(p = 0.03, F-test)$ .
				Pairwise comparison demonstrated $\uparrow$ depression scores at different timepoints: 1) time point 3 for those non-carriers of the GT haplotype compared to those carrying one copy of GT at time point 3 $(p < 0.01)$ . At timepoints 1 and 3, those non-carriers of the GT haplotype showed $\uparrow$ depression scores than those carrying two copies of the
				GT $(p = 0.01; p = 0.01)$ . $\uparrow$ depression scores were found at timepoint 1 compared to timepoint 2 in all three haplotype groups (0 GT: p < 0.001, 1 GT: p < 0.01, 2 GT: p < 0.00001). There was an $\uparrow$ in depression scores from timepoint 2 to timepoint 3 for non-carriers of a GT haplotype (p = 0.01) and for carriers of two copies of GT (p < 0.001).

				Haplotype block B1:  SNPs: rs6582071, rs11178997, rs1117899; Haplotypes: CAT, CGA, CGT, TAA  Results are identical to those from haplotype block A described above.  Haplotype block B3: Block B3 resulted in four haplotypes (GAA, TAA, TA, TTG) with the most common being TTA. 33% of those
				carrying <b>two copies</b> and 51.8%^ carrying <b>one copy</b> .  Linear mixed model: Those carrying <b>two copies</b> of <b>TAA</b> (0.6%) were joined with the carriers of <b>one copy of TAA</b> (15.5%). An effect for <b>time</b> was shown ( $p < 0.00001$ , $F$ -test) as well as the interaction between <b>TAA</b> and <b>time</b> ( $p = 0.01$ , $F$ -test). Differences between the patient groups at <b>time 1</b> were seen for <b>TAA</b> , and <b>both genotype groups</b> were different between all three <b>time points</b> ( $p < 0.00001$ , $p < 0.00001$ , $p < 0.01$ ).
				Pairwise comparison: Three timepoints showed ↑ depression scores at time 1 and time 2 for TAA (0 TAA: $p < 0.0001$ , $I + 2$ TAA: $p < 0.0001$ ). At time 2 and 3, an ↑ in depression scores was seen in both groups (0 TAA: $p = 0.03$ , $I + 2$ TAA: $p = 0.02$ ), and depression scores were ower at time 1 compared to time 3 (0 TAA: $p < 0.01$ , $I + 2$ TAA: $p < 0.01$ ).
				SNPs outside of haplotype blocks: rs10879354 (T/T + T/C vs C/C) showed an effect for time $(p < 0.00001)$ and SNP $(p = 0.04)$ but not for interaction.
				Pairwise comparison of the three timepoints showed $\uparrow$ depression scores at time 1 compared to time 2 $(p < 0.00001)$ ; time 2 compared to time 3 indicated a depression score $\uparrow$ $(p < 0.001)$ ; time 3 was $\uparrow$ than time 1 $(p < 0.01)$ .
				Six SNPs (T-703G, T-473A, A90G, C2755A, C10662T, G93329A) were noted from the <i>TPH2</i> gene.
				Two SNPs were found in the <u>cases</u> ( $T$ -473 $A$ , $p = 0.042$ ; $A$ 90 $G$ , $p = 0.038$ ) that were not found in <u>controls</u> .
Lin <sup>2</sup> (2009) (N = 200) <i>Taiwan</i>	To determine whether cytokines and kynurenine metabolites can predict the development of depression in pregnancy.	Cross- sectional <sup>1</sup>	В	Risk analysis showed that the "A" allele conferred a risk $(RR = 1.73; 95\% CI: 1.59-1.88)$ and demonstrated a dominant gene effect (A-allele carrier vs non-A allele carrier, $AC$ vs $CC$ ; $p = 0.038$ ).
				A strong linkage disequilibrium in the 5' region between <b>SNPs -703A</b> and <b>A90G</b> in both groups ( $D$ ' ranged from $0.87$ to $1$ ) and the $D$ ' dropped as the distance between the pairs of markers $\uparrow$ ( $D$ ' ranged from $0.50$ - $0.76$ ).
				The <b>GTAA</b> haplotype, which contains the risk 2755A allele, was different among <u>patients</u> and <u>controls</u> (Fisher's exact test, $p = 0.044$ ); however, the significant in distribution of the <b>GTAA</b> haplotypes disappeared in a rigid permutation test $(p = 0.086)$ .
Murakami <sup>2</sup> (2008) (N = 865) Japan	To examine the association between dietary GI and glycemic load (GL)	Prospective <sup>2</sup>	Bh	Compared with <b>dietary glycemic index (GI)</b> in the <u>first quartile</u> , <b>dietary GI</b> in <u>the third quartile</u> , but not the <u>fourth</u> was <i>associated</i> with ↓ risk of <u>PP</u> depression. <i>Multivariate ORs</i> (95% Cis) for <u>PP</u> depression for each of the <u>four quartiles</u> were: 1.00 (reference), 0.68 (0.39-1.17), 0.56

and postpartum	(0.32-0.995, p = 0.048), and $0.72$ $(0.41-1.26)$ , respectively
depression.	(p for trend = 0.18).

Author<sup>2</sup> = secondary analysis; Design<sup>#</sup> = Design + Number of timepoints investigated; Domain of factors investigated in relation to depression: B = Biological, Bh = Behavioral, E = Environmental, S = Social; *Values (when provided)* = statistical values respective to analysis; Factors investigated in relation to depression **bold;** Timeframe and/or groups investigated <u>underlined.</u>

®Study reported race/ethnicity

Of the 25 articles included in the final review, 80% of the articles were published in 2011 or later [30–49]. Though the US maternal mortality rates continue to markedly exceed that of other high-income countries [50], over half (60%) of the studies [31–34,36,39–41,45–48,51–53] were conducted outside of the US. Overall, sample sizes ranged from 16 to 3,252 (N = 9,481). Notably, sample sizes were much lower in studies conducted in the US (n = 1,407, M = 141, SD = 127) [30, 35, 37, 38, 42–44, 49, 54, 55] compared to non-US based studies (n = 8,074, M = 538, SD = 872.4) [31–34, 36, 39–41, 45–48, 51–53]. To determine if the difference was statistically significant, a Mann-Whitney U Test was performed using the open-source software tool R v.2022.12.0+353 but did not demonstrate a statistically significant difference (U = 50, p = 0.1775). However, the observable difference in sample sizes causes pause for concern related to studies being sufficiently powered and potential limitations of existing evidence. Thus, we deemed these findings to warrant further investigation to better understand implications and possible explanations for the evident difference.

### Upstream considerations for maternal mental health science

A total of four [33, 42–44] of the 25 studies discuss conducting an *a prior* power analysis to calculate the needed sample size with half of those being US based studies [37, 42]. However, of the two US based studies reporting a power analysis, one [37] does not report the calculated sample size nor if the study was sufficiently powered. Though power analysis was only reported in 16% of the 25 total studies, over half (60%) [32, 34–38, 40, 41, 43, 46, 48, 49, 52, 53, 54] note a small sample size as a study limitation. The percentage of US versus non-US based studies reporting sample size as a study limitation was equal at 60% each. Given a majority of the studies do not discuss power and 60% of the

total included studies note a small sample size as a study limitation, all interpretations for subsequent findings should be interpreted with caution.

We suspected secondary use of data from government or publicly available datasets with large sample sizes would explain the difference in sample sizes between US versus non-US based studies. Though nearly half of the studies were secondary analysis (48%) [38, 40, 41, 43–47, 49, 50, 53, 57], no studies explicitly reported the use of government or publicly available datasets. Secondary analyses accounted for 50% of the US based studies (50%) [40, 44, 47, 50, 57] versus 46.7% of non-US based studies [38, 41, 43, 45, 46, 49, 53]. Given our secondary analysis assumption was false, we investigated if differences in sources of research funding may account for differences in sample sizes as sources of funding may impact study budgets. Of the 20 studies [33–35, 37, 38, 40–43, 45–54, 57] that reported sources of funding, eight were from the US [33, 40, 42, 47, 50–52, 57] and 12 [34, 35, 37, 38, 41, 43, 45, 46, 48, 49, 53, 54] were non-US based studies. Of the eight in the US, seven studies [33, 40, 42, 47, 50, 52, 57] were federally funded whereas 9 non-US based studies [37, 41, 43, 45, 46, 48, 49, 53, 54] reported support from federal funding. Such findings suggest that though non-US based funding is slightly more diverse than US based funding sources, as expected, federal funding accounts for a majority of US and non-US based research.

Since federal funding sources (e.g., National Institutes of Health [NIH]) are among the largest sources of research funding, these findings prompted us to evaluate the scope of federal funding allocated to maternal depression research. It is important to note that an in-depth analysis respective to research funding budgets is beyond the scope of the present review and here we report the number of publications coming from federally funded projects and the number of federally funded projects to date on maternal depression. We used NIH RePORTER to approximate the number of publications funded by NIH projects on "maternal depression" to compare US versus non-US based research

(reporter.nih.gov). Steps for this process can be seen in Fig 2. The initial search yielded 36,425 publications supported by 906 core projects (ranging from 1985 to 2023). Once duplicate publications and publications not specific to maternal depression were removed (i.e., infant outcomes, other nonperinatal population outcomes), only 136 (0.37%) US based publications under 93 (10.3%) core projects (1991-2022) and 131 (0.36%) non-US based publications under 99 (10.9%) core projects (2002-2022) remained from the initial search total of 36,425 publications and 906 core projects. These findings suggest there is not a substantial difference by country in the number of publications or core projects related to maternal depression, and that the amount of funding allocated to maternal depression research may be overinflated once accounting for funding that does not have maternal outcomes as a primary focus. For this reason, we also examined the project funding data from NIH RePORTER, irrespective of country and publication, to understand how many maternal depression focused projects have been federally funded to date. A total of 3,488 project results from 1985-2023 were returned for "maternal depression." However, similar to publications, once duplicate projects were accounted for and projects with primary outcomes on persons other than perinatal persons were removed, only 158 projects (4.5%) spanning over 38 years remained. Of the 158 projects, 92 (58.2%) were intervention studies. Further, a number of southern states have some of the highest maternal mortality rates and/or poor maternal mental health outcomes yet were among the lowest funded states for investigations on maternal depression (e.g., Louisiana (0), Arkansas (0), Mississippi (0), New Mexico (0), Kentucky (1), Texas (4)) [1, 8, 58– 60].

#### Fig 2. Steps for NIH RePORTER data acquisition

These findings establish the first federally funded project in the US on perinatal depression began 38 years ago indicating perinatal mental health is a relatively new area of investigation, yet temporal trends in funding appear to be partial to intervention-based studies. Further, scientists appear to

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

be largely relying on secondary use of data to generate new knowledge which inevitably limits study design and methodological decisions. Though further investigation is warranted, the use of secondary data may be a product of budget limitations specific to maternal mental health focused research and consequently result in inadequately powered studies that challenge advancements in maternal mental health science and care. The rising maternal mortality and morbidity rates and evidence of perinatal depression having short-term and long-term health consequences for the offspring and familial unit positions maternal mental health as a public health issue. Given every person develops within a maternal environment for up to 9.5 months, it is imperative that maternal mental health gains recognition as a public health issue and sources of funding begin to prioritize maternal mental health science and care, especially in those states with higher disease burden and mortality rates. Collectively, these findings may partly explain why knowledge gaps persist and health disparity gaps continue to widen.

## **Participant characteristics**

Of the 21 studies [33, 35–38, 40-45, 47-50] that reported sample age (88%), the mean age of participants was 29.49 (2.71) years. Race and/or ethnicity was reported in nine [36, 40, 42, 44, 48, 50–52, 57] of the 25 studies (36%), but only five studies [40, 44, 50, 51, 57] (20%) included race/ethnicity in the analyses. Further, eight [36, 40, 42, 44 50–52, 57] of the nine studies that reported race/ethnicity were studies conducted within the US and 66.7% of those studies [40, 42, 44, 51, 52, 57] had samples comprised predominantly of Non-Hispanic White individuals. Meaning, existing knowledge on determinants of perinatal depression may exclude minority populations which have the highest rates of perinatal depression and maternal mortality and morbidity rates in the US [1,11, 58–60]. Of the 15 studies [35, 36, 40–42, 44–46, 48–53, 55, 57] that reported participant education, 80% [35, 40, 42, 44, 45, 49–53, 55, 57] had samples primarily comprised of individuals with at least some college education. Nine studies [36, 38, 40, 41, 44, 45, 48, 49, 52] reported income and/or SES with 88.8% [36, 38, 40, 41, 41, 42, 43, 44, 45, 48, 49, 52] reported income and/or SES with 88.8% [36, 38, 40, 41, 41, 42, 43, 44, 45, 48, 49, 52] reported income and/or SES with 88.8% [36, 38, 40, 41, 41, 42, 43, 44, 45, 4

44, 45, 49, 52] including a significant number (i.e., ≥50% of total sample) of participants from low to middle class. Nearly half (44%) of the studies [36, 38, 39, 45, 49–52, 55–57] reported parity with only one study [49] specifically looking at first-time mothers.

These demographic factors are important to consider because current evidence suggests those from lower SES and/or first-time mothers may be at increased risk of developing perinatal depression; however, there is conflicting evidence for education being a risk factor versus a protective factor.

Demographic information is collected routinely at prenatal visits, and though largely un-modifiable, may aid in detecting risk and providing evidence for clinical decisions on who warrants prenatal depression screening to temporally monitor symptoms and the need for intervention. Therefore, future studies may want to examine how different prenatal cohort demographics in clinical settings serve as predictors of postpartum depression (PPD). Such investigations hold potential to leverage the use of existing data with large sample sizes to inform how routinely collected clinical data can be aggregated and translated into mechanisms for perinatal depression risk screening and provide evidence to inform clinical decisions in who to screen during pregnancy.

The support of a partner is commonly suggested to be a protective factor for perinatal depression, yet partner status was only reported in eight (32%) [33, 36, 44, 45, 49, 50, 52, 53] of the 25 studies. Further, three studies [36, 50, 52] had at least half of the sample comprised of single individuals, and five studies [44, 45, 50, 53] controlled for partner status in the analyses. Interestingly, only two studies [38, 49] reported the mode of delivery (8%), and four studies (16%) [37, 38, 47, 56] reported breastfeeding status. In the US, the overall cesarean delivery rate increased by 60% from 1996-2009 (20.7% to 32.9%), and then experienced a slight decline in 2019 (31.7%) before increasing again in 2020 (31.8%) and 2021 (32.1%) [61]. Though the COVID-19 pandemic may explain the most recent increase in cesarean deliveries, growing evidence indicates there are psychological consequences

associated with cesarean deliveries, especially in the context of emergency cesarean deliveries [61] and for Black/African American delivering persons [62]. Regarding breastfeeding status, the direction and association of breastfeeding and perinatal depression has been controversial as some studies indicate breastfeeding as a protective factor [63]. Conversely, it has been indicated that perinatal depression may result in early cessation or that difficulties with breastfeeding may contribute to perinatal depression symptoms. Thus, mode of delivery and breastfeeding status may be important variables to consider in future investigations given the potential for psychological implications.

# **Methodological factors**

There were 9 prospective cohort studies [39, 41, 46, 48, 50–52, 54, 57], eight cross-sectional studies [34, 36, 38, 40, 43–45, 47], and six case-control studies [33, 35, 37, 49, 53, 56]. There was also one pilot study [42] and one randomized control trial [55]. The most common types of analytic methods applied were those looking at group differences (92%), correlations (52%), and regression (36%) while more complex forms of analyses, such as, mixed effects modeling (8%) and path analysis (2%) were the least common. All studies conducting biospecimen collection [33–40, 42, 43, 47–52, 54, 56, 57, 64] provided methods for processing and analyzing of the samples, though the level of detail provided was variable. All biospecimen samples were blood except for three studies that also collected either saliva [48], fecal [42], or urine [57] samples in addition to blood samples. A total of six [33, 35, 36, 50, 52, 56] studies reported the time of biospecimen collection, and one study reported requiring fasting (12 hours) when collecting blood samples [35].

Though not unexpected, the Edinburgh Postnatal Depression Scale (EPDS) was the most used instrument to measure depression (60%) [33, 35, 37–39, 42, 46–49, 51, 52, 54, 56, 57] followed by the Center for Epidemiological Studies Depression (CES-D) (16%) [36, 40, 44, 55]. Only 20% of the

studies [41–43, 50, 53] utilized semi-structured interviews to measure depression for purposes other than group allocation (i.e., depressive, control) and/or study eligibility. Of the 15 studies using EPDS to measure depression, 40% did not report a specified cut-off score [39, 42, 47, 49, 51, 57]. The nine studies [33, 35, 37, 38, 46, 48, 52, 54, 56] reporting EPDS cut-off scores varied between 9-13. The most common cut-off score was 10 (33.3%) [38, 48, 56], which is lower than the current clinically recommended cut-off score of  $\geq$ 13 [66]. Of the seven studies [35, 37, 38, 46, 48, 54, 56] using an EPDS cut-off score other than  $\geq$ 13, only three studies (28.6%) [35, 37, 46] provided scientifically supported rationales for using an alternative cut-off score. The US Preventive Services Task Force indicated 10 and 13 as the most common cut-off scores used [10]. A recent individual participant data meta-analysis suggested that using a cut-off score of  $\geq$  11 may be preferable due to combined sensitivity and specificity being maximized [67, 68]. However, the current recommendation of  $\geq$ 13 has remained unchanged since it was developed by Cox and colleagues (1987) nearly four decades ago in a postpartum sample in the United Kingdom.

As determined by quality appraisal assessments, concerns for risk of bias were noted or were unclear related to the following types of bias: 13 (52%) selection bias, 3 (12%) recall bias, and 24 (96%) measurement bias. **Fig 3**. A narrative description of risk of bias considerations for each included article is detailed in **S1 Table**. Moderate level of risk was noted in six studies for selection bias [35, 40, 41, 43, 45, 47], one for recall bias [40], and zero for measurement bias, whereas high level of risk was noted in two studies for selection bias [44, 46], two for recall bias [53, 57], and two for measurement bias [49, 53]. Further, a majority of the studies (88%) were indicated as having an unclear risk of bias for measurement bias largely due to studies not providing sufficient information or references to support the use of the measurement with respect to their sample characteristics and/or cut-off scores. For instance, Sha and colleagues (2022) conducted a study in a non-Swedish sample (US based sample) but

referenced a study validating the Swedish version of the EPDS in pregnancy. Another example is that of Miller and colleagues (2018) who used CESD to measure perinatal depression, and their supporting reference was a study assessing the efficacy of the instrument for use as screener for depression in community residing older adults (50-96 years of age).

#### Fig 3. Summary of level of risk of bias per study. aUS based study.

Further, it is important to note the items comprising the EPDS were adopted from existing scales mainly developed in the United Kingdom (UK) in non-perinatal populations of variable age (16-65) [66, 69–71]. The sample characteristics described by Cox and colleagues (1987) are is incongruent with all 15 studies that reported using the EPDS. A total of 10 (66.7%) studies [33, 37, 41, 42, 46–51] cite Cox and colleagues (1987) with 60% of these studies [33, 37, 42, 49–51] using this reference to substantiate the validity and reliability of the instrument and/or cut-off score for use in their study though there are notable differences in sample characteristics (i.e., country, mode of delivery, social class, relationship status, language). Though the EPDS is currently considered "gold standard" for measuring perinatal depression, increased inclusion of supporting references and/or scientifically supported rationales may be particularly useful to aid in decreasing variability in cut-off scores by collectively establishing best practices for determining cut-off scores respective to sample characteristics.

### Methodological considerations

As evidenced by the findings in this review, insufficient evidence is being provided for instrument selection in measuring perinatal depression. Without robust measures for primary outcome or group allocation variables, the risk of compromising the integrity of subsequent findings and the wider body of evidence is high. Though the instrument has remained unchanged in nearly four decades, social and political norms for child-bearing persons and marginalized groups have evolved since instrument

inception in the 1980's. Therefore, while it is common knowledge amongst maternal mental health scientists that the EPDS or CESD are widely used to assess perinatal depression, it is important the scientific community stay diligent in questioning the utility of instruments, especially when being used in diverse samples. Thus, the psychometric properties of the instrument continually need to be critically examined and it is important that supporting literature that is applicable to the present sample be referenced as to generate evidence for instrument validity and reliability across diverse samples, to establish best practices, and indicate when modifications and/or the development of new measures may be warranted.

Given the variability in cut-off scores and evidence suggesting perinatal depression may phenotypically differ between pregnancy and postpartum as well as from that of non-reproductive depression [73, 74], it is important for future investigations to consider the utility of existing perinatal depression measures for present day use. Such endeavors will aid in determining if and what modifications may be warranted to improve the scientific and clinical utility of perinatal depression measures. While we acknowledge the limitations of incorporating clinical interviews as a form of data collection (e.g., time constraints, burdensome to participants/staff, training, internal validity concerns), future investigations may be strengthened by conducting semi-structured interviews in addition to self-report measures when measuring perinatal depression. Incorporating two forms of measurement that yield two types of data (i.e., qualitative, quantitative) will not only strengthen any subsequent findings, but may also be particularly useful to progress our understanding of depression symptoms exclusive to perinatal populations and lead to advancements in life-stage informed measures that can increase precision in detection and timely intervention.

The bioavailability of essential amino acids (e.g., tryptophan, competitor amino acids), the precursors to a number of neurotransmitters commonly associated with psychiatric conditions, depends

on dietary intake. Thus, biospecimen collection respective to timing of food consumption is likely important to consider in investigations including essential amino acids and its metabolites as levels may significantly vary depending on when sample collection takes place. Yet no studies reported biospecimen collection time in relation to timing of food consumption suggesting this is not common practice. Free (non-albumin bound) tryptophan (TRP) is what can be transported across the blood-brain-barrier (BBB) to make it available in the brain for serotonin synthesis [22]. Conversely, it has been suggested that TRP has a higher affinity for the BBB than for albumin, and albumin bound TRP close to the BBB may separate from albumin to then transport across the BBB. Meaning, measurement of both free and total TRP is likely important in the study of psychiatric conditions, but only one study [34] specified if free and/or total TRP was measured. For these reasons, it is important for future investigations including essential amino acids to 1) consider biospecimen collection times in relation to timing of food consumption to advance our understanding of tryptophan metabolism in the perinatal period and 2) to clarify if free and/or total TRP is being measured as such considerations are essential for making meaningful interpretations of the findings.

Lastly, each type of biospecimen and method for processing and analyzing of samples introduces bias innate to the specified type and method [65]. Therefore, decisions on what type of biospecimen(s) to collect and methods of analysis warrant thoughtful consideration. As evidenced by the articles included in this review, there is a need for increased transparency in reporting of methods and rationales to support such methods. Transparency is vital not only for the purposes of reproducibility but also to collectively establish best practices for methods of biological sample selection, collection, processing, and analysis. Overall, these findings suggest that methods of investigation in maternal mental health science have room for improvement and can be strengthened with increased attention and reporting of sufficiently supported methodological decisions and processes, such as those discussed in this review.

By strengthening the methods of investigation in maternal mental health science, we can progress standards for best practices as well as mitigate the risk of generating conflicting findings that are a result of unsound methods rather than true conflicting findings.

## **Biological determinants**

A total of 20 studies [33–40, 42–44, 47–52, 54, 56, 57] investigated biological determinants of perinatal depression. Inflammatory markers were investigated in 10 studies [33, 35, 36, 40, 44, 48, 50–52, 57], tryptophan and/or tryptophan metabolites in seven studies [33, 34, 42, 49, 52, 54, 56], genetic polymorphisms in three studies [37, 39, 43], micronutrient alterations in two studies [35, 38], and neurological factors in one [47], respectively.

### Inflammatory markers and oxidative stress

TNF- $\alpha$  (pro-inflammatory cytokine) was positively correlated with prenatal depression and those with prenatal depression had higher TNF- $\alpha$  levels compared to those without [35, 44]. Miller and colleagues (2018) found that even when controlling for sociodemographic factors, those with prenatal depression unresponsive to antidepressant treatment and those with untreated prenatal depression had higher TNF- $\alpha$  levels compared to those with prenatal depression that responded to antidepressant treatment. These findings suggest that TNF- $\alpha$  may be a useful biomarker for determining a subtype of perinatal depression that is treatment resistant to antidepressants. However, it is important to note Miller and colleagues (2018) do not specify specific antidepressants used for treatment nor the duration of treatment. Additionally, intimate partner violence is commonly indicated as a risk factor for perinatal depression. Robertson-Blackmore and colleagues (2016) found a history of intimate partner violence to be positively associated with TNF- $\alpha$ . Also suggesting interpersonal relationships have potential to induce inflammatory responses, Ross and colleagues (2018) found romantic partner relationships low in

both negative (e.g., conflict) and positive (e.g., support, intimacy) features to be associated with lower anti-inflammatory cytokines (IL-10, IL-13) and higher pro-inflammatory profile (IL-6:IL-10 ratio). Whereas Finy and colleagues (2018) found past (i.e., childhood abuse) and current adversities (i.e., lower SES) to be positively associated with elevations in inflammatory markers (i.e., CRP, IL-6).

A positive association among depression symptoms and IL-6 (involved in both immune response and inflammation) was found [40, 48] and even when controlling for pre-pregnancy body mass index (BMI), higher depression scores were positively associated with both IL-6 and TNF- $\alpha$  [36]. Similarly, Achytes and colleagues (2020) found, even after adjusting for demographic factors and pharmacological treatment, that postpartum individuals with elevated plasma levels of IL-6, IL-8 (pro-inflammatory cytokine), and TNF-α (modest) had increased odds of PPD, while a decrease in IL-2 (pro-inflammatory cytokine) increased the odds of PPD. Plasma IL-10 (anti-inflammatory cytokine) and IL-1β (proinflammatory cytokine) were not associated with increased risk for PPD. Results from Sha and colleagues (2022) support the aforesaid findings specific to IL-6 but not for IL-1\beta. Moreover, IL-1\beta was found to be negatively associated with depression scores across four-time points (i.e., three trimesters, one postpartum time point). Findings from Sha and colleagues (2022) also suggest a potential secondtrimester biomarker panel (IL-6, TNF- $\alpha$ , quinolinic, and kynurenine) to predict PPD. Conversely, Christian and colleagues (2009) found that depression scores were positively correlated with IL-2 and IL-10, and Robertson-Blackmore and colleagues (2016) did not find depressive symptoms at 32 weeks' gestation to be associated with IL-6 or TNF- $\alpha$ . Differences in perinatal timepoints assessed and methodological decisions may explain conflicting results.

Across the pregnancy period depression was positively associated with oxidative stress, as measured by 8-isoprostane (considered a stable biomarker of oxidative stress) in urine, and oxidative stress mediated the relationship between prenatal depression and spontaneous preterm birth [57]. While

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

sources of oxidative stress vary, evidence suggests the sources are largely related to environmental and lifestyle factors. Therefore, it may be meaningful to investigate factors that influence oxidative stress in the perinatal period in relation to associated health outcomes (i.e., depression, spontaneous preterm birth) to explore how such factors may be attenuated and leveraged for risk mitigation.

### Tryptophan pathway, metabolites, and neurotransmitters

Brain TRP availability was negatively associated with plasma competitor amino acid concentrations during the postpartum period (+77% isoleucine, +55% leucine, +52% tyrosine) and the intensity of postpartum "blues" [34]. It is important to note that though we acknowledge postpartum blues as different than PPD, the difference is largely the duration of symptoms as postpartum blues is considered transient. The timepoint investigated by Bailara and colleagues (2006) was three days postpartum, meaning it is unknown if these symptoms were in fact transient or if symptoms continued beyond study participation and were later considered PPD. Therefore, for transparency, we retained the use of the term postpartum blues and decided to include these findings given the findings are consistent with those in non-perinatal populations yet is understudied in perinatal populations [22, 79].

Plasma levels of serotonin and neuropeptide Y (stimulates food intake, particularly carbohydrates) were lower in those with PPD [49]. Conversely, dopamine (role in movement, motivation, pleasure) and norepinephrine (role in flight-or-fight response) were higher in those with PPD compared to controls. Achytes and colleagues (2020) also found that lower plasma serotonin increased the risk of PPD, whereas absolute plasma levels of TRP did not affect the risk of PPD. Though not specific to depression, Achytes and colleagues (2020) also found that suicide, a distal outcome of depression and a leading cause of maternal mortality, was associated with lower levels of plasma serotonin and lower plasma serotonin increased the odds of a completed suicide attempt during

pregnancy even when adjusting for EPDS scores. Though such findings require further investigation, serotonin may be significant biomarker of suicide risk in perinatal populations.

Prenatally, plasma levels of kynurenine (KYN) and kynurenic acid (KA) were significantly higher in the depressed group compared to the non-depressed group. Postpartum, higher plasma levels of KYN, KA, and KYN/TRP and KYN/KA ratios were observed in the PPD group compared to those in the non-depressed group [54]. Sha and colleagues (2022) found quinolinic acid, a neurotoxic TRP metabolite that gets synthesized via the KYN pathway, to be associated with depression in the third trimester. Higher plasma levels of quinolinic acid were associated with both increased severity and risk of falling into a category of clinically significant symptoms (i.e., EPDS ≥13). In non-perinatal populations with depression, inflammation is suggested to play a role in the shunting of TRP down the KYN pathway and KYN has become increasingly recognized as a potential link between inflammation and depression [22, 80]. KYN has also been linked with sleep disturbances, a common depression symptom, which is also commonly experienced perinatally [80, 81]. Poor sleep has also been widely established as a risk factor for a number of chronic health conditions. For these reasons, it may be beneficial for future research to explore such interactions and the directionality of said interactions as they relate to perinatal depression onset, chronicity, and risk for comorbidities.

Conversely, Veen and colleagues (2016) found KYN to be significantly lower in patients with perinatal depression compared to non-depressed controls. Similarly, findings from Nazzari and colleagues (2020) suggest a negative association among prenatal KYN levels and depression symptoms in late pregnancy and postpartum after adjusting for maternal age. No differences were found in the plasma levels of TRP or its metabolites among perinatal depressed groups compared to non-depressed controls [54, 56]. Kimmel and colleagues (2022) found no significant associations among TRP/serotonin related metabolites or bile acids and depression. While three studies [42, 48, 56] provided conflicting

results related to KYN levels, differences in the timepoints assessed, the country where the study took place, and differences in methodological decisions may explain the conflicting results as lifestyle choices and psychosocial and environmental factors are likely quite different between countries. Two of the three studies [42, 56] were also likely underpowered as one was a pilot study with a sample size of 30 and the second had a sample size of 42, with 23 being cases of PPD while the remaining were controls. Lastly, as previously discussed, sleep disturbances have been linked to the KYN pathway and depression, and inflammation is suggested to increase the shunting of TRP down the kynurenine pathway. However, five of the seven studies examining TRP did not consider inflammation as a variable in their study nor did any of the seven studies assess sleep. Inflammation and sleep disturbances are both commonly experienced perinatally which may explain why these factors have been overlooked; however, for the reasons discussed, they are important factors to consider in the context of perinatal depression.

## Genetic Polymorphisms

Catechol-O-methyltransferase (*COMT*) is a gene that provides instruction for the metabolization of catecholamine neurotransmitters (i.e., epinephrine, norepinephrine, dopamine). A common functional polymorphism studied in relation to psychiatric conditions is the *COMT* variant, *Val*<sup>158</sup>*Met* (rs4680), where an amino acid change of valine [val] to methionine [met] is suggested to reduce the activity of the COMT enzyme that metabolizes the aforesaid neurotransmitters [82–84]. This polymorphism is suggested to influence cognition and behavior in psychiatric conditions, such as depression. Though the *COMT* variant is minimally explored in perinatal depression, Comasco and colleagues (2011) found an association among the polymorphism (*COMT-Val*<sup>158</sup>*Met*) and PPD symptoms at 6 weeks but not at 6 months. Additionally, genetic variation in the Monoamine oxidase A (*MAOA*) gene is suggested to contribute to depression, specifically when *MAOA* activity is high. Higher gene activity occurs when

there is a polymorphism in rs1137070 where a C allele replaces a T. Higher *MAOA* activity induced by this polymorphism may result in rapid catalyzation of the neurotransmitters serotonin and norepinephrine [85]. However, a meta-analysis suggests the T variant is associated with major depression in non-pregnant populations [86]. With regard to gene-gene interactions, Comasco and colleagues (2011) found *COMT-MAOA* interactions to be significantly associated with PPD symptoms. For instance, among low *MAOA* carriers (T allele), the *Met* variant of the *COMT* gene was related to PPD symptoms; whereas the high *MAOA* variant (C allele) was related to PPD symptoms only when combined with the *Met* allele of *COMT*. In terms of gene-environment interactions, *COMT-Val*<sup>158</sup>*Met* was also associated with PPD symptoms when psychiatric history and stress were present. This interaction effect may explain why studies have reported significant associations of both *MAOA* polymorphisms with depression.

Two studies explored polymorphisms of tryptophan hydroxylase 2 (*TPH2*), the rate limiting enzyme of serotonin biosynthesis, in those with perinatal depression [39, 43]. The *TPH2* gene plays a major role in the regulation of the neurotransmitter serotonin, and genetic variants of *TPH2* are suggested to play a significant role in both susceptibility to depression and response to a commonly prescribed treatment, selective serotonin reuptake inhibitors (SSRIs) [87, 88]. Lin and colleagues (2009) found that the *TPH2 C2755A* polymorphism occurred only in those with perinatal depression and/or an anxiety disorder. Further, though significance faded after Bonferroni correction, a risk analysis demonstrated that the *TPH2 C2755A* polymorphism increased risk of perinatal depression and exhibited a dominant gene effect. However, it is important to note the reported study is specific to a Han Chinese population, and the authors position this polymorphism as a potential population specific indictor of depression risk based these findings and current evidence in Han Chinese populations. Also exploring *TPH2* polymorphisms, Fasching and colleagues (2012) found the single-nucleotide polymorphism

(SNP) in intron 8 (rs10879354) to be the only SNP to show consistent effects across all time points (≥ 31 weeks gestation, 48-72 hours postpartum, 6-8 months postpartum) in a German population. Since *TPH2* polymorphisms influence the activity of neurotransmitters commonly associated with depression in non-perinatal and perinatal populations [87, 88], it would be beneficial for future investigations to further examine potential genetic biomarkers and their influence on relevant metabolic pathways. Progressing this area of inquiry will not only improve the odds of discovering a genetic biomarker for perinatal depression risk but may also advance our understanding of population specific biomarkers which could drastically increase precision in early detection and intervention.

#### Micronutrient alterations

A negative association among vitamin B12, cobalamine deficiency (cB12), and serotonin were observed with probable PPD [38]. Adequate amounts of B12 are suggested to be particularly important in pregnancy for both the pregnant person as well as the offspring given its role in nervous system health [89, 90]. Concurrent with folate, B12 aids in DNA synthesis as well as red blood cell production.

Interestingly, dietary sources considered high in B12 (i.e., animal-based proteins) are also sources high in TRP, the precursor to serotonin [91]. In the same study [38], a positive association was found among Methylmalonic acid (MMA) (suggested marker of functional deficiency of vitamin B12), homocysteine (hey) (broken down by B12 and folic acid; elevated levels suggest vitamin deficiency), and 5 methyltetrahydrofolic acid (5-methyl THF) (suggested marker of a folate/methyl trap due to existing B12 deficiency) and depression symptoms. Further, elevated MMA and 5-methyl THF were found to be significant predictors of probable PPD, and MMA was suggested to be a potential mediator of PPD.

Other micronutrient alterations that were associated with prenatal depression were total n-3 polyunsaturated fatty acids (n-3 PUFA), eicosapentaenoic acid (EPA), and docosahexaenoic acid

(DHA). EPA and DHA are two notably important fatty acids given they are critical for the development and function of the central nervous system in both perinatal persons and the developing fetus and have anti-inflammatory properties [92]. Chang and colleagues (2018) found that those with prenatal depression had lower levels of total n-3 PUFA, EPA, and DHA compared to those without prenatal depression. Prenatal depression duration was negatively correlated with total n-3 PUFA, EPA, and DHA. These findings indicate micronutrient deficiencies, either due to low dietary consumption and/or an existing functional deficiency, may be useful measures for detecting perinatal depression risk or early symptom onset. Though supplementation of B12 has provided conflicting results, reviews and metaanalyses of RCTs have shown the fatty acids discussed can improve depression symptoms in perinatal and non-perinatal populations and may be useful as an independent or adjuvant treatment modality depending on the individual [92–94]. This is particularly important to note for perinatal populations as pharmacological interventions are not highly desired in pregnant or breastfeeding persons due to concerns for potential implications on the developing offspring [95, 96]. Thus, though future research is needed, micronutrient supplementation may be desirable option for those at risk or those exhibiting mild depressive symptoms during pregnancy to serve as form of risk mitigation and indirect health promotion strategy for the developing offspring.

### Neurological alterations

Brain serotonin-1A (5HT1A) receptor binding potential, as measured by positron emission tomography (PET), suggested a 20-28% reduction in postsynaptic 5HT1A receptor binding in those experiencing PPD [47]. The most significant reductions were found to be in the anterior cingulate (related functions - emotional expression, attention, mood regulation) and mesiotemporal cortices which includes the amygdala (input and processing of emotion) and hippocampus (episodic memory). Likely due to methods of data acquisition and the unknown risks for perinatal individuals and their offspring,

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

investigations into neuroanatomical features and their respective roles in perinatal specific depression are sparse. While there are some conflicting findings, the present findings are consistent with some literature on depression and/or anxiety in non-perinatal populations [98, 99].

### **Behavioral determinants**

Six studies [33, 38, 41, 45, 46, 55] investigated behavioral determinants of perinatal depression. Dietary intake was investigated in three studies [38, 45, 46] whereas suicide (i.e., attempts, ideation, risk) was explored in two [33, 41]. Physical activity [55] and functional impairment [41] were each explored in one.

Though specific to the third quartile (ascending quartiles per glycemic index/load), Murakami and colleagues (2008) found higher dietary glycemic index (GI) decreased the risk of PPD, while no associations were found between PPD and dietary glycemic load (GL). Lower milk, meat, and egg consumption during the postpartum period was associated with probable PPD [38]. Further, even after adjusting for potential dietary and non-dietary confounding factors, higher tryptophan intake was independently negatively associated with depressive symptoms in pregnancy [45]. TRP, the precursor to the neurotransmitter serotonin that is commonly associated with depression, is an essential amino acid. Essential amino acids, such as TRP, are only made available through dietary intake as they are not independently produced by the body [22]. Though Dhiman and colleagues (2021) did not specifically examine TRP, animal and plant-based proteins (i.e., milk, meat, eggs, spirulina, nuts and seeds) are among some of the highest sources of TRP. Thus, together these findings indicate lower dietary consumption of TTRP in the perinatal period may contribute to increased risk of depression onset which is consistent with findings from animal and human studies in non-perinatal populations [19, 22, 73, 74]. Additionally, though not a variable noted in any of the included studies, nausea and vomiting due to "morning sickness"

or hyperemesis gravidarum (severe type of morning sickness) occurs in roughly 70% of pregnancies. Thus, these variables may be particularly important to consider in investigations of TRP metabolism perinatally as these variables are likely to increase risk for depletion of essential nutrients vital for maternal and fetal health.

Two studies independently demonstrated alcohol consumption [41] during pregnancy or a high risk of suicide (i.e., current and past attempts and ideation) [33, 41] increased the odds of being classified into the perinatal depression group. Those endorsing higher functional impairment had increased odds of being classified in the perinatal depression group [41] whereas a single randomized control trial (RCT) [55] demonstrated a prenatal physical exercise program to decrease the risk of PPD. The RCT consisted of 60-minute sessions three times per week starting at 12-16 weeks gestation and found the percentage of people reporting depression was lower in the intervention group than in the control group at both 38 weeks gestation and 6 weeks' postpartum. The findings related to substance abuse, history of suicide attempts or current suicidal ideation, and exercise are consistent with existing literature. Conversely, functional impairment is a less commonly studied factor [75]. Functional impairment is a marked feature of clinical depression yet is not routinely assessed, if at all, during the period. Exploring the implications of functional impairment in the perinatal period may be particularly useful to clinically monitor for declines from baseline functioning for those with and without pre-existing disabilities or functional impairments. Further research in this area may help advance detection strategies for life-stage specific onset or exacerbations of pre-existing functional impairment that may not otherwise be visible to clinicians and provide evidence for identifying individuals in need of increased support. While we understand these behavioral factors may increase the risk of PPD and behavioral interventions targeting such factors may aid in mitigating risk, it is important to consider who is disproportionately impacted by perinatal

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

depression and the broader contextual factors that serve as potential barriers and are beyond the immediate control of the individual (e.g., social determinants of health).

### Social and environmental determinants

A total of seven studies [36, 37, 40, 41, 50, 51, 53] investigated social and environmental determinants of perinatal depression. Five studies investigated significant life events (e.g., trauma, intimate partner violence, history of childhood abuse) [37, 40, 41, 50, 53] and social support [36, 37, 40, 41, 51]. Perceived stress was investigated in two studies [36, 37] and unhappiness with pregnancy [37] and food insecurity [41] were investigated in one study.

Two commonly suggested risk factors of perinatal depression, psychiatric history [37] and significant life events [37, 40, 41, 50, 53], were positively associated with perinatal depression [76, 77]. Even after adjusting for sociodemographic factors, personal history of depression, and timing of depression onset, those reporting a history of childhood trauma were at higher risk of PPD, anxiety, and suicide attempts than those without [53]. A dose effect was present between the number of childhood trauma types and risk of PPD. Robertson-Blackmore and colleagues (2016) examined lifetime exposure to intimate partner violence and found lifetime intimate partner violence to increase the likelihood of experiencing perinatal depression. For those currently endorsing frequent hostile and insensitive social interactions experienced an increase in prenatal depressive symptoms [36]. Further, there was a negative relationship among social support and depression symptoms, and low social support served as a significant predictor of perinatal depressive symptoms [36, 41, 51]. Relatedly, higher negative qualities in one's interpersonal relationships were associated with greater depressed mood, perceived stress, and pregnancy distress [51]. Collectively, these findings indicate the level of past exposure, type of exposure, and current appraisal of interpersonal relationships may moderate one's level of risk for PPD.

Consistent with current evidence, perceived stress was positively correlated with perinatal depression [36, 37, 40, 51]. Being unhappy about one's pregnancy was also positively correlated with perinatal depression [36]. Such findings are particularly important to note for US based research given the current political and social climate related to child-bearing age person's rights and abortion access. Irrespective of one's personal views on the matter, the recent changes in federal and state level regulations are likely to increase rates of perinatal depression and subsequently result in a surge of negative health outcomes in both perinatal persons and the offspring. Fox and Brod (2021) investigated the cost of perinatal complications in the US for all 2019 births from conception to age 5 and found such complications to result in \$32.2 billion in societal costs (i.e., healthcare expenses, loss of productivity, social support services) [78]. It was also suggested these estimates likely underrepresent the totality of the financial burden. This analysis was conducted prior to federal and state level changes on abortion access and a global pandemic. Despite spending more on healthcare than any other developed country, the US and its healthcare system have yet to gain control over the rising maternal mortality and morbidity rates. Meaning the US is likely not prepared to manage a surge in perinatal health complications, especially so soon after a global pandemic. Therefore, advancements in maternal mental health care are vital for individual and systemic health. Future investigations to further examine unhappiness with pregnancy as a potential risk factor as well as diligent monitoring of trends in incidence since the change in regulations are necessary to generate evidence for increased resources and support.

One study [41] found food insecurity to predict perinatal depression in two groups (i.e., prenatal only depression, prenatal and postpartum depression) and the odds of experiencing depression both prenatally and in the postpartum was 2.5 greater in the presence of food insecurity. Interestingly, non-perinatal specific research that began examining the impact of COVID-19 on food insecurity found food

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

insecurity to disproportionately impact racial and ethnic groups, and the states with the highest projected food insecurity rates based on overall population occurred in states that also have some of the highest maternal mortality rates (i.e., Louisiana, Texas) [76]. These findings suggest food insecurity as a potential predictor of PPD and demonstrates the importance of post-pandemic science to consider the remnant effects of global pandemics on perinatal health.

### **Prospective interactions**

The specific factors explored across the four domains were highly variable. Therefore, this review does not claim to present an exhaustive description of all potential interactions that can be interpreted from findings of the aggregated factors. Due to patterns in which interactions with TRP and its metabolites emerged, we specifically chose to focus on these interactions as they may suggest a potential role in perinatal depression risk and onset.

Although minimally explored in perinatal populations, disruption in serotonin or the serotonergic system is widely considered to contribute to depression onset, maintenance, and response to treatment (i.e., SSRIs) in non-perinatal populations [88, 98, 99]. Some evidence suggests the disruption of the serotonergic system is more prominent in biologically born females compared to males, and that the dysregulation of serotonin may partly explain why biologically born females experience depression at two times the rate of biologically born males. Given TRP is the precursor to serotonin, brain TRP availability is vital for adequate production of the neurotransmitter serotonin. Other essential amino acids (e.g., isoleucine, leucine, phenylalanine) compete with TRP to cross the BBB and are the precursors to several other neurotransmitters (e.g., dopamine, norepinephrine) that are implicated in psychiatric conditions [79, 100]. Consistent with current evidence indicating TRP competes with other essential amino acids to cross the BBB, Bailara and colleagues (2016) found a negative association

among brain TRP availability and competitor amino acid concentrations, notably one of which was tyrosine, a precursor of dopamine and norepinephrine. Since essential amino acids (i.e., TRP, isoleucine, leucine, phenylalanine) are not independently produced by the body and depend on dietary intake for availability, dietary habits, food accessibility, and other factors that may influence changes in metabolic activity (e.g., genetic polymorphisms, morning sickness, breastfeeding, comorbid conditions) are particularly important to consider in this area of inquiry. A majority of the studies in this review examining TRP and its metabolites did not concurrently examine or control for dietary habits, micronutrients, and/or food accessibility; however, a majority of the studies that did examine such factors independent of TRP found associations with PPD [35, 38, 41, 46].

The mechanisms underlying the increased uptake of TRP in the brain are not fully understood, but some evidence suggests higher dietary carbohydrate intake can promote the uptake of TRP in the brain resulting in increased serotonin [100, 101]. Interestingly, Rihua and colleagues (2018) found plasma levels of serotonin and neuropeptide Y (stimulates food intake, particularly carbohydrates) [102, 103] to both be lower in those with PPD. Achytes and colleagues (2020) also found lower levels of plasma serotonin to increase risk of PPD but did not denote increased risk of PPD related to plasma TRP. However, they did note an elevated KYN/serotonin ratio was associated with an increased risk of PPD. TRP degradation into KYN is suggested to increase in response to immune and inflammatory activation in non-perinatal populations experiencing depression [19, 22, 104, 105]. Since pregnancy naturally induces immune and inflammatory responses in the pregnant individual to accommodate the developing fetus, TRP degradation into KYN may occur more often during this life-stage and increase one's risk for depression. Veen and colleagues (2016) did not explore the aforesaid in the pregnancy period, but they did find this to be the case in the physiological postpartum period.

Though the life-stage itself induces a unique immune and inflammatory response, additional factors throughout the perinatal period, such as the social, environmental, and behavioral factors discussed in this review (e.g., stress, social support, intimate partner violence) may further promote immune and inflammatory responses and increased TRP degradation down the KYN pathway predisposing one to depression onset. Further, sleep disturbances are common perinatally and are often attributed to "normal" pregnancy and postpartum symptoms, but sleep disturbances also happen to be a common symptom of depression and/or anxiety in non-perinatal populations. Though sleep disturbances are linked to the TRP and KYN pathways, they are not considered in any study in this review yet may serve as a moderating factor that perpetuates a negative feedback loop which contributes to chronicity or a risk for symptom relapse, notably in the postpartum period due to poor quality of sleep as a result of child rearing responsibilities. Meaning, certain biochemical pathways may account for specific depression symptoms and indicate subtypes of perinatal depression that can be leveraged to increase precision in detection and intervention.

In the context of PPD, these findings may indicate when dietary intake of tryptophan or tryptophan uptake promoting foods are limited amid immune and inflammatory responses, competitor amino acids are being prioritized for transport across the BBB and/or TRP may be shunted towards the KYN pathway. Moreover, both pathways may result in decreased production of the neurotransmitter serotonin and explain the risk for and onset of PPD, and the level of risk would be further increased for those with a genetic predisposition (i.e., genetic polymorphisms) or those experiencing the other biopsychosocial or behavioral factors discussed in this review. Thus, future investigations are needed to further explore these prospective interactions as these interactions may serve as significant risk factors of PPD that can be detected and intervened upon during pregnancy.

### **Conclusion**

The factors discussed in this review have been independently indicated as probable determinants of PPD risk and onset. However, what is not evident in independent investigations but is demonstrated in this review is that various interactions among diverse determinants and TRP metabolism may provide a deeper understanding of what contributes to the pathophysiology of perinatal depression or perinatal depression risk. Future investigations are needed to address methodological issues in maternal mental health science and care as well as explore these prospective interactions as these interactions hold potential to evolve as a PPD risk phenotype (observable characteristics). Such a phenotype can serve as a robust foundation for the development of clinically efficient yet meaningful mechanisms for risk detection and inform patient centered risk mitigation strategies. Further, the present review establishes the value of integrative approaches in the investigation of perinatal depression and suggests the application of team science principles (e.g., collaboration, diverse expertise) may be particularly useful to this area of inquiry to expedite the discovery of clinically relevant findings and strengthen scientific methods.

### Acknowledgments

Thank you to all the authors and participants for your contributions in progressing maternal mental health science and care by either conducting or participating in the studies discussed in this review.

### References

- 1. Trost SL, Beauregard J, Chandra G, Nije F, Berry J, Harvey A, et al. Pregnancy-related deaths:
- Data from maternal mortality review committees in 36 US states, 2017–2019. 2022 Sep.
- Dagher RK, Bruckheim HE, Colpe LJ, Edwards E, White DB. Perinatal depression: Challenges
- and opportunities. J Womens Health. 2021 Feb 1;30(2):154–9.

- 760 3. American Congress of Obstetricians and Gynecologists (ACOG) Committee. Screening for
- perinatal depression. Committee Report. Washington (DC); 2015. Report No.: 757. Available
- from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.utexas.edu/30629567/
- 4. American Psychiatric Association (APA). Depressive disorders. In: Diagnostic and statistical
- manual of mental disorders: DSM-5 (5<sup>th</sup> ed.). Arlington: American psychiatric publishing Inc.
- 765 2013.
- 5. American Congress off Obstetricians and Gynecologists (ACOG). Opioid use and opioid use
- disorder in pregnancy committee on obstetric practice American society of addiction medicine.
- Report. 2021. Available from: http://www.integration.samhsa.gov/
- 6. Admon LK, Dalton VK, Kolenic GE, Ettner SL, Tilea A, Haffajee RL, et al. Trends in suicidality
- 1 Year before and after birth among commercially insured childbearing individuals in the United
- 771 States, 2006-2017. JAMA Psychiatry. 2021 Feb 1;78(2):171–6.
- 7. Campbell J, Matoff-Stepp S, Velez ML, Cox HH, Laughon K. Pregnancy-associated deaths from
- homicide, suicide, and drug overdose: Review of research and the intersection with intimate
- partner violence. J Womens Health. 2021 Feb 1;30(2):236–44.
- 775 8. Texas Department of States Health Services (DSHS). The Role of opioid overdoses in confirmed
- maternal deaths, 2012-2015. Report. 2017. Available from:
- 777 https://www.dshs.texas.gov/mch/DSHS-Maternal-Mortality-and-Morbidity-Presentations-and-
- 778 Publications/.asp
- 779 9. Emerson MR, Mathews TL, Struwe L. Postpartum depression screening for new mothers at well
- 780 child visits. MCN Am J Matern Child Nurs. 2018;43(3):139–45.
- 781 10. Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Interventions to
- prevent perinatal depression: US Preventive Services Task Force recommendation statement. Vol.

- 783 321, JAMA Journal of the American Medical Association. American Medical Association; 2019.
- 784 p. 580–7.
- 785 11. Bauman BL, Ko JY, Cox S, D'Angelo DV, Warner L, Folger S, et al. Vital signs: postpartum
- depressive symptoms and provider discussions about perinatal depression United States, 2018.
- 787 MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):575–81.
- 788 12. Van Niel MS, Payne JL. Perinatal depression: A review. Cleve Clin J Med. 2020 May;87(5):273–
- 789 7.
- 790 13. Yim IS, Tanner Stapleton LR, Guardino CM, Hahn-Holbrook J, Dunkel Schetter C. Biological and
- 791 psychosocial predictors of postpartum depression: Systematic review and call for integration.
- 792 Annu Rev Clin Psychol. 2015 Mar 28;11(1):99–137.
- 793 14. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The
- management of depression during pregnancy: a report from the American Psychiatric Association
- and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009
- 796 Sep;31(5):403–13.
- 15. Hutchens BF, Kearney J. Risk factors for postpartum depression: An umbrella review. Vol. 65,
- Journal of Midwifery and Women's Health. John Wiley and Sons Inc.; 2020. p. 96–108.
- 799 16. Biaggi A, Conroy S, Pawlby S, Pariante CM. Identifying the women at risk of antenatal anxiety
- and depression: A systematic review. J Affect Disord. 2016 Feb;191:62–77.
- 17. e Couto C, Martins Brancaglion MY, Alvim-Soares A, Moreira L, Garcia FD, Nicolato R, et al.
- Postpartum depression: A systematic review of the genetics involved. World J Psychiatry.
- 803 2015;5(1):103.

- 18. Yang YC, Schorpp K, Boen C, Johnson M, Harris KM. Socioeconomic status and biological risks
- for health and illness across the life course. J Gerontol B Psychol Sci Soc Sci. 2020 Feb
- 806 14;75(3):613–24.
- 19. Dell'Osso L, Carmassi C, Mucci F, Marazziti D. Depression, serotonin and tryptophan. Curr
- 808 Pharm Des. 2016 Feb 15;22(8):949–54.
- 809 20. Beck CT. Predictors of Postpartum Depression. In: Nursing Research. Philadelphia: Wolters
- 810 Kluwer; 2001. Vol. 50. p. 275-285.
- 21. Guintivano J, Manuck T, Meltzer-Brody S. Predictors of postpartum depression: A comprehensive
- review of the last decade of evidence. Vol. 61, Clinical Obstetrics and Gynecology. Lippincott
- Williams and Wilkins; 2018. p. 591–603.
- 22. Dougherty DM, Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N. L-
- 815 Tryptophan: Basic metabolic functions, behavioral research and therapeutic indications. Vol. 2,
- International Journal of Tryptophan Research. 2009.
- 23. Groer M, Fuchs D, Duffy A, Louis-Jacques A, D'Agata A, Postolache TT. Associations among
- obesity, inflammation, and tryptophan catabolism in pregnancy. Biol Res Nurs. 2018 May
- 819 1;20(3):284–91.
- 820 24. Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to
- modern treatment target. Vol. 16, Nature Reviews Immunology. Nature Publishing Group; 2016.
- p. 22–34.
- 25. Abu-Raya B, Michalski C, Sadarangani M, Lavoie PM. Maternal immunological adaptation during
- 824 normal pregnancy. Vol. 11, Frontiers in Immunology. Frontiers Media S.A.; 2020.

- 26. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
- 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021 Mar
- 827 29;18(3):e1003583.
- 828 27. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
- systematic reviews. Syst Rev. 2016 Dec 5;5(1):210.
- 28. American Psychiatric Association (APA) [Internet]. APA Dictionary of Psychology. [cited 2023]
- June]. Available from: https://dictionary.apa.org/
- 29. Healthy People 2030 [Internet]. Social Determinants of Health. [cited 2023 June]. Available from:
- https://health.gov/healthypeople/priority-areas/social-determinants-health
- 30. Critical Appraisal Skills Programme (CASP) [Internet]. Cohort study, case-control study,
- randomized control trial Checklist. 2018. [cited 2023 June]. Available from: https://casp-
- uk.net/casp-tools-checklists/
- 31. Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to
- assess the quality of cross-sectional studies (AXIS). 2016. Available from:
- http://dx.doi.org/10.1136/bmjopen-2016-011458
- 32. Handley SL, Dunn TL, Waldron G, Baker JM. Tryptophan, cortisol and puerperal mood. British
- Journal of Psychiatry. 1980 May 29;136(5):498–508.
- 33. Achtyes E, Keaton SA, Smart L, Burmeister AR, Heilman PL, Krzyzanowski S, et al.
- Inflammation and kynurenine pathway dysregulation in post-partum women with severe and
- suicidal depression. Brain Behav Immun. 2020 Jan;83:239–47.
- 845 34. Bailara K, Henry C, Lestage J, Launay J, Parrot F, Swendsen J, et al. Decreased brain tryptophan
- availability as a partial determinant of post-partum blues. Psychoneuroendocrinology. 2006
- 847 Apr;31(3):407–13.

- 35. Chang JPC, Lin CY, Lin PY, Shih YH, Chiu TH, Ho M, et al. Polyunsaturated fatty acids and
- inflammatory markers in major depressive episodes during pregnancy. Prog
- Neuropsychopharmacol Biol Psychiatry. 2018 Jan;80:273–8.
- 36. Christian LM, Franco A, Glaser R, Iams JD. Depressive symptoms are associated with elevated
- serum proinflammatory cytokines among pregnant women. Brain Behav Immun. 2009
- 853 Aug;23(6):750–4.
- 37. Comasco E, Sylvén SM, Papadopoulos FC, Sundström-Poromaa I, Oreland L, Skalkidou A.
- Postpartum depression symptoms. Psychiatr Genet. 2011 Feb;21(1):19–28.
- 38. Dhiman P, Pillai RR, Wilson AB, Premkumar N, Bharadwaj B, Ranjan VP, et al. Cross-sectional
- association between vitamin B12 status and probable postpartum depression in Indian women.
- 858 BMC Pregnancy Childbirth. 2021 Dec 17;21(1):146.
- 39. Fasching PA, Faschingbauer F, Goecke TW, Engel A, Häberle L, Seifert A, et al. Genetic variants
- in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. J
- Psychiatr Res. 2012 Sep;46(9):1109–17.
- 40. Finy MS, Christian LM. Pathways linking childhood abuse history and current socioeconomic
- status to inflammation during pregnancy. Brain Behav Immun. 2018 Nov;74:231–40.
- 41. Garman EC, Schneider M, Lund C. Perinatal depressive symptoms among low-income South
- African women at risk of depression: trajectories and predictors. BMC Pregnancy Childbirth. 2019
- 866 Dec 14;19(1):202.
- 42. Kimmel M, Jin W, Xia K, Lun K, Azcarate-Peril A, Plantinga A, et al. Metabolite trajectories
- across the perinatal period and mental health: A preliminary study of tryptophan-related
- metabolites, bile acids and microbial composition. Behavioural Brain Research. 2022
- Feb;418:113635.

- 43. Lin YMJ, Ko HC, Chang FM, Yeh TL, Sun HS. Population-specific functional variant of the
- TPH2 gene 2755C>A polymorphism contributes risk association to major depression and anxiety
- in Chinese peripartum women. Arch Womens Ment Health. 2009 Dec 9;12(6):401–8.
- 44. Miller ES, Grobman WA, Culhane J, Adam E, Buss C, Entringer S, et al. Antenatal depression,
- psychotropic medication use, and inflammation among pregnant women. Arch Womens Ment
- 876 Health. 2018 Dec 4;21(6):785–90.
- 45. Miyake Y, Tanaka K, Okubo H, Sasaki S, Arakawa M. Tryptophan intake is related to a lower
- prevalence of depressive symptoms during pregnancy in Japan: baseline data from the Kyushu
- Okinawa Maternal and Child Health Study. Eur J Nutr. 2022 Dec 27;61(8):4215–22.
- 46. Murakami K, Miyake Y, Sasaki S, Tanaka K, Yokoyama T, Ohya Y, et al. Dietary glycemic index
- and load and the risk of postpartum depression in Japan: The Osaka Maternal and Child Health
- 882 Study. J Affect Disord. 2008 Sep;110(1–2):174–9.
- 47. Moses-Kolko EL, Wisner KL, Price JC, Berga SL, Drevets WC, Hanusa BH, et al. Serotonin 1A
- receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril.
- 885 2008 Mar;89(3):685–92.
- 48. Nazzari S, Molteni M, Valtorta F, Comai S, Frigerio A. Prenatal IL-6 levels and activation of the
- tryptophan to kynurenine pathway are associated with depressive but not anxiety symptoms across
- the perinatal and the post-partum period in a low-risk sample. Brain Behav Immun. 2020
- 889 Oct;89:175–83.
- 890 49. Rihua X, Haiyan X, Krewski D, Guoping H. Plasma concentrations of neurotransmitters and
- postpartum depression. Journal of Central South University Medical Sciences. 2018;43(3):274–81.

- 892 50. Robertson Blackmore E, Mittal M, Cai X, Moynihan JA, Matthieu MM, O'Connor TG. Lifetime
- 893 Exposure to Intimate Partner Violence and Proinflammatory Cytokine Levels Across the Perinatal
- Period. J Womens Health. 2016 Oct;25(10):1004–13.
- 895 51. Ross KM, Miller G, Qadir S, Keenan-Devlin L, Leigh AKK, Borders A. Close relationship
- qualities and maternal peripheral inflammation during pregnancy. Psychoneuroendocrinology.
- 897 2017 Mar;77:252–60.
- 898 52. Sha Q, Madaj Z, Keaton S, Escobar Galvis ML, Smart LA, Krzyzanowski S, et al. Cytokines and
- tryptophan metabolites can predict depressive symptoms in pregnancy. Transl Psychiatry. 2022
- 900 Dec 1;12(1).
- 53. Tebeka S, Le Strat Y, Etain B, Ray M, Mullaert J, Dubertret C. Childhood trauma and perinatal
- depression. J Clin Psychiatry. 2021 Sep 7;82(5).
- 903 54. Teshigawara T, Mouri A, Kubo H, Nakamura Y, Shiino T, Okada T, et al. Changes in tryptophan
- metabolism during pregnancy and postpartum periods: Potential involvement in postpartum
- depressive symptoms. J Affect Disord. 2019 Aug 1;255:168–76.
- 906 55. Vargas-Terrones M, Barakat R, Santacruz B, Fernandez-Buhigas I, Mottola MF. Physical exercise
- programme during pregnancy decreases perinatal depression risk: a randomised controlled trial. Br
- 908 J Sports Med. 2019 Mar;53(6):348–53.
- 909 56. Veen C, Myint AM, Burgerhout KM, Schwarz MJ, Schütze G, Kushner SA, et al. Tryptophan
- pathway alterations in the postpartum period and in acute postpartum psychosis and depression. J
- 911 Affect Disord. 2016 Jan; 189:298–305.
- 912 57. Venkatesh KK, Meeker JD, Cantonwine DE, McElrath TF, Ferguson KK. Association of antenatal
- depression with oxidative stress and impact on spontaneous preterm birth. Journal of Perinatology.
- 914 2019 Apr 5;39(4):554–62.

915 58. World Health Organization (WHO) [Internet]. Trends in maternal mortality 2000 to 2017: 916 Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division, 2019. [cited 2023 June]. Available from: https://apps.who.int/iris/handle/10665/327596 917 918 59. Texas Health and Human Services [Internet]. Revised - Texas Maternal Mortality and Morbidity 919 Review Committee and Department of State Health Services Joint Biennial Report. 2022. [cited 920 2023 June]. Available from: https://www.dshs.texas.gov/sites/default/files/legislative/2020-Reports/DSHS-MMMRC-2020.pdf 921 60. Centers for Disease Control and Prevention (CDC) [Internet]. Maternal deaths and mortality rates: 922 923 Each state, the District of Columbia, United States, 2018-2020, [cited 2023 June]. Available from: 924 https://www.cdc.gov/nchs/maternal-mortality/mmr-2018-2021-state-data.pdf 61. Howell EA, Mora PA, Horowitz CR, Leventhal H. Racial and ethnic differences in factors 925 926 associated with early postpartum depressive symptoms. Vol. 105, Obstetrics and Gynecology. 2005. p. 1442–50. 927 62. Centers for Disease Control and Prevention (CDC) [Internet]. Pregnancy mortality surveillance 928 929 system. 2022. [cited 2023 June]. Available from: 930 https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-931 system.htm 63. Osterman J. K. M. Changes in primary and repeat cesarean delivery: United States 2016-2021. 932 Atlanta, Georgia; 2022 Jul. 933 934 64. Valdes EG. Examining cesarean delivery rates by race: A population-based analysis using the

robson ten-group classification system. J Racial Ethn Health Disparities. 2021 Aug 17;8(4):844–

54

51.

935

- 937 65. Pope CJ, Mazmanian D. Breastfeeding and postpartum depression: An overview and
- methodological recommendations for future research. Depress Res Treat. 2016:1–9.
- 939 66. Miller MJ, Kennedy AD, Eckhart AD, Burrage LC, Wulff JE, Miller LAD, et al. Untargeted
- metabolomic analysis for the clinical screening of inborn errors of metabolism. J Inherit Metab
- 941 Dis. 2015 Nov 15;38(6):1029–39.
- 942 67. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: Development of the 10-item
- Edinburgh Postnatal Depression scale. British Journal of Psychiatry. 1987;150(JUNE):782–6.
- 68. Levis B, Negeri Z, Sun Y, Benedetti A, Thombs BD. Accuracy of the Edinburgh Postnatal
- Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum
- women: systematic review and meta-analysis of individual participant data. BMJ. 2020 Nov
- 947 11;m4022.
- 948 69. Qiu X, Wu Y, Sun Y, Levis B, Tian J, Boruff JT, et al. Individual participant data meta-analysis to
- compare EPDS accuracy to detect major depression with and without the self-harm item. Sci Rep.
- 950 2023 Mar 10;13(1):4026.
- 70. Snaith RP, Constantopoulos AA, Jardine MY, McGuffin P. A clinical scale for the self-assessment
- of irritability. British Journal of Psychiatry. 1978 Feb 29;132(2):164–71.
- 71. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983
- 954 Jun.
- 955 72. Bedford A, Foulds GA, Sheffield BF. A New Personal Disturbance Scale (DSSI/sAD). British
- 956 Journal of Social and Clinical Psychology. 1976 Nov;15(4):387–94.
- 957 73. Wright ML, Podnar J, Longoria KD, Nguyen TC, Lim S, Garcia S, Wylie D. Comparison of
- commercial DNA extraction kits for whole metagenome sequencing of human oral, vaginal, and

- rectal microbiome samples. bioRxiv. 2023 Feb 2:2023-02. Available from: https://pubmed-ncbi-
- 960 nlm-nih-gov.ezproxy.lib.utexas.edu/36778319/
- 74. DeMyer MK. Plasma tryptophan and five other amino acids in depressed and normal subjects.
- 962 Arch Gen Psychiatry. 1981 Jun 1;38(6):642.
- 963 75. Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020 Jan 12;25(1):131–
- 964 47.
- 76. Cho HJ, Savitz J, Dantzer R, Teague TK, Drevets WC, Irwin MR. Sleep disturbance and
- kynurenine metabolism in depression. J Psychosom Res. 2017 Aug:99:1–7.
- 967 77. Opmeer EM, Kortekaas R, van Tol MJ, van der Wee NJA, Woudstra S, van Buchem MA, et al.
- Influence of COMT val158met genotype on the depressed brain during emotional processing and
- 969 working memory. PLoS One. 2013 Sep 12;8(9):e73290.
- 78. Dickinson D, Elvevåg B. Genes, cognition and brain through a COMT lens. Neuroscience. 2009
- 971 Nov;164(1):72–87.
- 972 79. Sheikh HI, Kryski KR, Smith HJ, Dougherty LR, Klein DN, Bufferd SJ, et al. Catechol-O-
- 973 methyltransferase gene val158met polymorphism and depressive symptoms during early
- childhood. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2013
- 975 Apr;162(3):245–52.
- 80. Naoi M, Riederer P, Maruyama W. Modulation of monoamine oxidase (MAO) expression in
- 977 neuropsychiatric disorders: genetic and environmental factors involved in type A MAO
- 978 expression. J Neural Transm. 2016 Feb 22;123(2):91–106.
- 81. Liu Z, Huang L, Luo XJ, Wu L, Li M. MAOA Variants and Genetic Susceptibility to Major
- Psychiatric Disorders. Mol Neurobiol. 2016 Sep;53(7):4319–27.

- 82. Liu ZL, Wang XQ, Liu M fan, Ye B juan. Meta-analysis of association between TPH2 single
- nucleotide poiymorphism and depression. Neurosci Biobehav Rev. 2022 Mar;134:104517.
- 983 83. Gao J, Pan Z, Jiao Z, Li F, Zhao G, Wei Q, et al. TPH2 Gene polymorphisms and major depression
- 984 A meta-analysis. PLoS One. 2012 May 31;7(5):e36721.
- 985 84. Rogne T, Tielemans MJ, Chong MFF, Yajnik CS, Krishnaveni G V., Poston L, et al. Associations
- of maternal vitamin B12 concentration in pregnancy with the risks of preterm birth and low birth
- weight: A systematic review and meta-analysis of individual participant data. Am J Epidemiol.
- 988 2017 Jan 20.
- 989 85. Finkelstein JL, Layden AJ, Stover PJ. Vitamin B-12 and perinatal health. Advances in Nutrition.
- 990 2015 Sep;6(5):552–63.
- 991 86. National Institutes of Health (NIH) Office of Dietary Supplements (ODS) [Internet]. Vitamin B12
- Fact Sheet for Health Professionals. 2022. [cited 2023 June]. Available from:
- 993 https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
- 994 87. Hsu MC, Tung CY, Chen HE. Omega-3 polyunsaturated fatty acid supplementation in prevention
- and treatment of maternal depression: Putative mechanism and recommendation. J Affect Disord.
- 996 2018 Oct;238:47–61.
- 997 88. Markun S, Gravestock I, Jäger L, Rosemann T, Pichierri G, Burgstaller JM. Effects of vitamin B12
- supplementation on cognitive function, depressive symptoms, and fatigue: A systematic review,
- meta-analysis, and meta-regression. Nutrients. 2021 Mar 12;13(3):923.
- 1000 89. Wolters M, von der Haar A, Baalmann AK, Wellbrock M, Heise TL, Rach S. Effects of n-3
- Polyunsaturated Fatty Acid Supplementation in the Prevention and Treatment of Depressive
- Disorders—A Systematic Review and Meta-Analysis. Nutrients. 2021 Mar 25;13(4):1070.

- 1003 90. Liao Y, Xie B, Zhang H, He Q, Guo L, Subramanieapillai M, et al. Efficacy of omega-3 PUFAs in
- depression: A meta-analysis. Transl Psychiatry. 2019 Aug 5;9(1):190.
- 91. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review
- focused on risks and controversies. Acta Psychiatr Scand. 2013 Feb;127(2):94–114.
- 92. Goodman JH. Women's attitudes, preferences, and perceived barriers to treatment for perinatal
- 1008 depression. Birth. 2009 Mar;36(1):60–9.
- 93. Labaka A, Goñi-Balentziaga O, Lebeña A, Pérez-Tejada J. Biological sex differences in
- depression: A systematic review. Biol Res Nurs. 2018 Jul 14;20(4):383–92.
- 94. Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. P5-HT1A receptors in mood and anxiety:
- recent insights into autoreceptor versus heteroreceptor function. Psychopharmacology (Berl). 2014
- 1013 Feb 12;231(4):623–36.
- 1014 95. Wang D, Wu J, Zhu P, Xie H, Lu L, Bai W, et al. Tryptophan-rich diet ameliorates chronic
- unpredictable mild stress induced depression- and anxiety-like behavior in mice: The potential
- involvement of gut-brain axis. Food Research International. 2022 Jul;157:111289.
- 96. Correia AS, Vale N. Tryptophan metabolism in depression: A narrative review with a focus on
- serotonin and kynurenine pathways. Int J Mol Sci. 2022 Jul 31;23(15):8493.
- 97. Posmontier B. Functional status outcomes in mothers with and without postpartum depression. J
- 1020 Midwifery Womens Health. 2008;53(4):310–8.
- 98. Blount AJ, Adams CR, Anderson-Berry AL, Hanson C, Schneider K, Pendyala G.
- Biopsychosocial factors during the perinatal period: Risks, preventative factors, and implications
- for healthcare professionals. Vol. 18, International Journal of Environmental Research and Public
- Health. MDPI AG; 2021.

- 1025 99. Yang K, Wu J, Chen X. Risk factors of perinatal depression in women: a systematic review and
- meta-analysis. BMC Psychiatry. 2022 Dec 1;22(1).
- 1027 100. Fox B, Brod M. Pregnancy and delivery complications cost the United States billions in health care
- expenses, lost productivity, and social support services. 2021 Nov.
- 1029 101. Feeding America [Internet]. The impact of the coronavirus on local food insecurity in 2020 &
- 1030 2021. Report. 2021 Mar. [cited 2023 June]. Available from:
- https://www.feedingamerica.org/research/coronavirus-hunger-research
- 1032 102. Mehedint MG, Gulledge A. Nutritional impact on cognitive development. In: Reference Module in
- Biomedical Sciences. Elsevier; 2014.
- 103. Pawluski JL, Li M, Lonstein JS. Serotonin and motherhood: From molecules to mood. Front
- 1035 Neuroendocrinol. 2019 Apr;53:100742.
- 1036 104. Markus CR. Dietary Amino Acids and Brain Serotonin Function; Implications for Stress-Related
- Affective Changes. Neuromolecular Med. 2008 Dec 31;10(4):247–58.
- 1038 105. Gao K, Pi Y, Mu CL, Farzi A, Liu Z, Zhu WY. Increasing carbohydrate availability in the hindgut
- promotes hypothalamic neurotransmitter synthesis: aromatic amino acids linking the microbiota-
- brain axis. J Neurochem. 2019 Jun;149(5):641–59.
- 1041 106. Huang Y, Lin X, Lin S. Neuropeptide Y and Metabolism Syndrome: An Update on Perspectives of
- 1042 Clinical Therapeutic Intervention Strategies. Front Cell Dev Biol. 2021 Jul 9;9.
- 1043 107. Beck B. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.
- Philosophical Transactions of the Royal Society B: Biological Sciences. 2006 Jul
- 1045 29;361(1471):1159–85.
- 1046 108. Neumeister A. Tryptophan depletion, serotonin, and depression: where do we stand?
- 1047 Psychopharmacol Bull. 2003;37(4):99–115.


Supporting information

S1 Table. Description of risk of bias considerations. Author<sup>2</sup> indicates the study was a secondary analysis. ®Study reported race and/or ethnicity.

S1 Checklist. PRISMA 2020 Checklist.

Financial disclosure statement

KDL is supported by the National Institute of Nursing Research of the National Institutes of Health (T32NR019035). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.



Duplicate records removed (N = 126)

medRxiv preprint doi: https://doi.org/10.1101/2023.08.02.23293552; this version posted August 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license.

Records screened (N = 328)

Records excluded (N = 302)

- Not in human (n = 156)
- · Grey literature/review metaanalysis (n = 65)
- No perinatal focus or depression focus (n = 62)
- <18 years old (n = 14)</li>
- Other exclusion criteria (n = 5)

Records included for full-text review

$$(N = 26)$$

Records excluded (n = 0)

Records included for quality appraisal screening

$$(N = 26)$$

Records excluded (n = 1)

Studies included in review (N = 25)

# NIH RePORTER

(Publications)

# NIH RePORTER

(Projects)

### Step 1

Search "maternal depression"

# Step 1

Search "maternal depression"

## Step 2

medRxiv preprint doi: https://doi.org/10.1101/2023.08.02.23293552; this version posted August 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license.

Publications (N = 36,425)

Projects (N = 906)

# Step 2

Export data
Projects (N = 3,488)

## Step 3

Remove duplicates, publications not specific to perinatal persons

Publications (N = 267)

Projects (N = 192)

# Step 3

Remove duplicates, publications not specific to perinatal persons

Projects (N = 158)

# Step 4

Separate US vs. Non-US studies

## Step 4

Organize data by state column

At the state level, projects were then quantified to assess funding in states with some of the highest maternal mortality and/or maternal mental health rates

 $\underline{\text{Lousiana}} \ (n = 0)$ 

 $\underline{Arkansas} (n = 0)$ 

 $\underline{\text{Texas}} (n = 3)$ 

# Step 5

**Publications** 

US (n = 136); Non-US (n = 131)

<u>Projects</u>

US (n = 93); Non-US (n = 99)

**Timeframes** 

1991-2022; 2002-2022

# Step 5

Quantify intervention studies

$$(N = 92)$$

\*Keywords searched (intervention, treatment, therapy, therapeutic)

Study	Domain	Perinatal period	Selection bias	Recall bias	Measurement bias	
<sup>a</sup> Achytes et al. (2022)	B, Bh	PP				Key:
<sup>a</sup> Kimmel et al. (2022)	В	PN				Low risk
<sup>a</sup> Sha et al. (2022)	В	PN				High risk
Dhiman et al. (2021)	В	PP				Moderate risk Unclear risk
Teshigawara et al. (2021)	В	PN				Oncical risk
Nazzari et al. (2020)	В	PN				P Pregnancy
aRoss et al. (2017)	B, S	P				PP Postpartum
medRxiv preprint doi: https://doi.org/10.1101/2023:08.02.282 (which was not certified by peer review) is the author/fu It is made available u	93552; this ver	sion posted A	ugust 2, 202: Xiv a license	3. The copyric to display th	ght holder for preprint in p	PN Perinatal this preprint erpetuity.
aRobertson-Blackmore et al. (2016)	B, S	PN				B Biological
Fasching et al. (2012)	В	PN				Bh Behavioral
Comasco et al. (2011)	B, S	PP				E Environmental
<sup>a</sup> Christian et al. (2009)	B, E	P				S Social
<sup>a</sup> Moses-Kolko et al. (2008)	В	PP				
Miyake et al. (2022)	Bh	P				
Garman et al. (2019)	Bh,S,E	PN				
Chang et al. (2018)	В	P				
Lin et al. (2009)	В	PN				
<sup>a</sup> Finy et al. (2018)	B, S	P				
<sup>a</sup> Miller et al. (2018)	В	P				
Murakami et al. (2008)	Bh	PN				
Rihua et al. (2018)	В	PP				
Veen et al. (2016)	В	PP				
Bailara et al. (2006)	В	PP				
Tebeka et al. (2021)	s	PP				
<sup>a</sup> Venkatesh et al. (2019)	В	P				